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Abstract of the Dissertation 
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Doctor of Philosophy In Biomedical Engineering 
The City University of New York 
2014 
 
Advisors: Hui B. Sun, PhD and Dr. Luis Cardoso, PhD 
 
Novel prevention and therapeutic treatment for cartilage degradation is urgently called 
for, as cartilage degradation is a hallmark for arthritic diseases including osteoarthritis (OA) and 
rheumatoid arthritis (RA), and there is a high incidence of arthritis-related disability and high 
medical costs.  While both underuse (e.g. physically inactive lifestyle) and overuse (e.g. high 
impact or intense repetitive joint use as seen in certain sports) are risk factors for cartilage 
degradation, recent studies highlight that dynamic moderate loading is associated with reduced 
incidence of developing OA. Exercise is prescribed in most cases at moderate levels for both OA 
and RA patients, and accumulating studies demonstrate appropriate exercise maintains cartilage 
homeostasis and may exert a role in chondroprotection, but the mechanisms underlying how 
mechanical signals are translated into chondroprotective actions are largely unknown.  
Identifying the molecules that mediate mechanotransduction and its mechano-responsive nature 
will not only provide a biomechanical basis for developing more effective mechanical loading-
based exercises for chondroprotection, but also can provide novel targets or molecular switches 
to develop chemical-based modalities for disease treatment. 
 The overall objectives of this dissertation were to determine the mechanical  response of 
transcriptional regulator CBP/p300 Interacting Transactivator with ED-rich Tail 2 (CITED2) to 
various mechanical loading regimes, elucidating CITED2-mediated chondroprotective pathways, 
and determining the potential of CITED2 as a target for the prevention and treatment of cartilage 
degradation in arthritis.  The global hypothesis was that CITED2 mediates a mechanical pathway 
of chondroprotection, CITED2 is required for cartilage integrity, and restoration or increasing 
levels of CITED2 exerts efficacy in the prevention and treatment of cartilage degradation.  This 
hypothesis was tested with four specific aims:  1) To determine the gene expression response of 
CITED2 to various mechanical loading regimes, and the role of CITED2 in mediating 
mechanical regulation of matrix metalloproteinases (MMPs), 2) To determine the CITED2-
mediated loading-induced pathway and test whether it is required for loading-induced 
downregulation of MMPs, 3) To determine whether deficiency of CITED2 is a causal factor for 
cartilage degradation in arthritic diseases such as OA, and 4) Test the concept of CITED2 as a 
target for chondroprotection. 
The key findings of this dissertation include: 1) CITED2 expression is induced by 
moderate dynamic loading in chondrocytes in an intensity- and duration-dependent manner, and 
the upregulation of CITED2 is sustained for at least 12 hours after loading.  The induction of 
CITED2 is required for the downregulation of MMPs (i.e. MMP-2, -3, and -13),  2) Dynamic 
moderate loading induces CITED2 by activating p38δ, which in turn triggers Sp1 and HIF-1α to 
transactivate CITED2.  CITED2 competes with MMP transactivator Ets-1 for binding to limiting 
amounts of co-factor p300, resulting in repression of MMP expression.  3) Deficiency of 
CITED2 is associated with cartilage degradation in human OA and disease progression of post-
traumatic OA in mice subject to destabilization of the medial meniscus (DMM).  Experimental 
knockdown of CITED2 caused cartilage degradation and deletion of CITED2 in adult cartilage 
not only resulted in an early OA phenotype, but also accelerated the disease progression of 
cartilage degradation in DMM mice, revealing a chondroprotective role of CITED2, which is 
required for cartilage integrity maintenance.  4) Restoring levels of CITED2, via gene transfer or 
small molecule epigallocatechin gallate (EGCG), exerts efficacy in slowing cartilage degradation 
in RA and OA mouse models.  Together, these studies provide feasibility for developing 
CITED2-activation-based therapies for the prevention and treatment of cartilage degradation. 
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Chapter 1.  Introduction and Background 
 
1.1 Research Significance 
Cartilage degradation is a hallmark of joint diseases such as osteoarthritis (OA) and 
rheumatoid arthritis (RA).1  These joint diseases result in joint pain accompanied by varying 
degrees of functional limitation and reduced quality of life. They affect more than 27 million 
Americans, and are one of the leading causes of pain and disability worldwide.2,3  In response to 
articular cartilage damage as seen in OA or RA, cartilage exhibits increased cell activity and new 
tissue production in an attempt to repair the damage.  However, the  intrinsic repair is limited and 
deregulated. Cartilage degradation is usually a continuous process, leading to erosion of the 
articular surface and eventual joint failure.2,4   
There is currently no cure or effective treatment for arthritis.  Treatments thus far mainly 
focus on the secondary effects of joint diseases such as pain and joint function, but there are no 
effective disease-modifying therapies for cartilage degradation.5,6 Potentially useful 
pharmacologic therapies (i.e. matrix metalloproteinase inhibitors) have seen limited clinical 
benefit, and severe side effects.7 A better understanding of the pathogenesis of cartilage 
degradation will be required to achieve significant advances in the development of effective 
strategies for the prevention and treatment of joint diseases such as OA and RA. 
Moderate exercise is the most common non-pharmacologic therapy prescribed to patients 
with arthritis.  The Arthritis Foundation promotes an exercise program involving low-impact 
physical activity, and participants have reported less pain and fatigue, and increased strength.8  
Clinical trials of patients with OA report physical activities including aerobic exercise, 
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stretching/flexibility, endurance training, aquatic exercise, and muscle strengthening lead to 
improvements in pain relief, body weight, and metabolic abnormalities.9  In addition to the 
symptom-modifying effects of exercise, there is evidence of exercise exerting disease-modifying 
effects.  For example, increased physical activity in the form of aerobic and weight-bearing 
exercises results in increased proteoglycan content, one of the major components of the cartilage 
extracellular matrix, in the cartilage of OA patients.10  Strength training for 30 months, compared 
to range of motion exercises alone, leads to a decreased mean rate of joint space narrowing.11 
While the clinical benefits of dynamic moderate exercise are significant, mechanisms 
underlying the effects of physical activity on the joint are not well understood.  Experimental 
studies in animal models of osteoarthritis and human cartilage tissues ex vivo suggest moderate 
exercise also leads to increased anti-catabolic, anti-inflammatory, and anabolic activity.2  
Dynamic stimulation of cartilage explants increases synthesis of cartilage matrix components 
and physiologic loading of animals with experimental osteoarthritis suppresses expression of 
inflammatory mediators (e.g. interleukin-1β and tumor necrosis factor-α) and enzymes which 
directly cleave the articular cartilage including matrix metalloproteinases (MMPs) and A 
Disintegrin And Metalloproteinase with Thrombospondin Motifs (ADAMTS).2  Focusing on 
elucidating the mechanisms underlying the chondroprotective effects of physiological joint 
loading may provide novel insights aimed at maintaining cartilage health. 
1.2. Joint Physiology in healthy cartilage 
Articular joints consist of two bony ends with cartilaginous end plates sheathed by a soft 
envelope of synovium.  The cartilaginous plates, consisting of chondrocytes and at least seven 
species of collagen, but mostly Type II, cushion the bony ends during repeated compression and 
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enable them to slide with minimal friction.12 The metabolic needs of the avascular cartilage are 
met by nutrients and waste products diffusing through the synovial fluid and into and out of the 
synovium and its blood vessels and lymphatics.13 Fat, collagen, and glycosaminoglycans 
constitute the deformable synovial sheath. Synovial lining cells synthesize joint lubricants, 
matrix molecules, digestive enzymes, and cytokines.12   
Cartilage structure and composition 
 Articular cartilage lines the ends of bones in synovial joints and provides an almost 
frictionless surface for motion.14   Cartilage is anueral and avascular and consists of one cell 
type:  the chondrocyte, which is embedded in an extracellular matrix (ECM) of collagen 
molecules and proteoglycans (PGs).  Chondrocytes account for approximately 5% of the total 
volume of the cartilage, while water constitutes 70-80% of the total tissue weight.15  Collagen 
molecules, of which type II is the predominant form, constitute about 75% of the dry tissue 
weight.  They form a matrix with tensile strength, which allows cartilage to resist swelling.15   
Aggrecan, which is the most abundant proteoglycan in cartilage, accounts for approximately 
25% of the dry tissue weight.16  Aggrecan monomers attach to hyaluronan to form large 
aggregating complexes within the cartilage fiber meshwork.  These monomers consist of a 
protein core to which numerous negatively charged glycoaminoglycans side chains attach.17  Due 
to this negative charge the PGs confer onto the extracellular matrix, the cartilage becomes 
hydrophilic, resulting in a swelling of the tissue which aids in load support and tissue recovery 
from deformations.18   
The structural properties of cartilage vary with its depth and the cartilage matrix can be 
categorized into a superficial, middle, and deep zone.  In the superficial zone, collagen fibers are 
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densely packed and aligned parallel to the articular surface, and chondrocytes appear flattened in 
shape.  Collagen fibers in the middle zone are randomly oriented and chondrocytes appear larger 
and more rounded than in the superficial zone.  Collagen fibers in the deep zone are oriented 
perpendicular to the bone and chondrocytes are aligned in radial columns.19  Aggrecan content is 
lowest in the superficial zone, highest in the middle, and decreases in the deep zone.20  The half-
life of aggrecan core protein ranges from 3 to 24 years.  The proteoglycans are essential for 
protecting the collagen network, which has a half-life of more than 100 years if not subjected to 
inappropriate degradation.21  Under homeostatic conditions, chondrocytes do not divide, and are 
responsible for maintaining the cartilage extracellular matrix through the synthesis of matrix 
components and remodeling of the matrix.22 
1.3. Cartilage degradation 
Osteoarthritis 
Osteoarthritis (OA) is the most common joint disease, affecting the structural and 
functional integrity of articular cartilage, as well as the adjacent bone and other joint tissues in an 
estimated 15% of the U.S. population.3  Clinical symptoms associated with OA include joint 
pain, stiffness, and swelling, which may lead to impaired physical function.23  OA is generally 
diagnosed radiographically by bony changes, including joint space narrowing, development of 
osteophytes,  subchondral sclerosis, and subchondral cyst formation.24  These clinical and 
radiographic features are most commonly diagnosed in the knee, hip, and hand joints.23   
Although the most evident morphological sign of OA is the progressive destruction of 
articular cartilage, and OA is classified as non-inflammatory arthritis, synovitis may also play a 
role in the progression of cartilage degradation.  Mononuclear cell infiltration and synovial and 
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subchondral angiogenesis are frequently present in OA joints,25-29 resulting in synovial 
hypertrophy and hyperplasia with an increased number of lining cells.26,30  Increased numbers of 
immune cells (e.g. activated B cells and T lymphocytes) in synovial tissue are also observed,31 
leading to the induction of cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-
α),29 and the production of proteases which target the cartilage extracellular matrix.30  These 
cartilage breakdown products can further provoke the release of degradative enzymes from 
synovial cells.32  Therefore, in developing therapeutic strategies against cartilage degradation, the 
effect of the adjoining joint tissues should be considered. 
Rheumatoid arthritis 
 Rheumatoid arthritis (RA) is a systemic inflammatory disease that produces a progressive 
degeneration of the musculoskeletal system.  RA is characterized by both joint inflammation and 
destruction of bone and articular cartilage.33  One of the most prevalent chronic conditions, RA is 
found in approximately 1% of the adult population in the United States.34  Disabilities associated 
with RA can lead to a restriction of regular daily activity and diminished quality of life.35  Even 
with appropriate drug therapy, up to 7% of patients remain disabled to some extent 5 years after 
disease onset and 50% are too disabled to work 10 years after onset.34  Consequently, RA results 
in considerable direct and indirect costs.   
Etiology and risk factors of OA 
The initiating factors of OA are unknown, and the exact temporal sequence of events 
involving changes in an early OA articular joint are not well defined.  However, risk factors for 
developing OA have been defined, and are broadly divisible into 1) biomechanical risk factors 
including joint injury, occupational/recreational over usage, reduced muscle strength, joint laxity, 
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joint malalignment, 2) constitutional factors such as ageing, gender and obesity, and 3) genetic 
factors.  Importantly, several risk factors are reversible (i.e. obesity, muscle weakness) or 
avoidable (i.e. recreational joint trauma) which has important implications for prevention.36   
Injuries of the knee articular cartilage surfaces are frequently observed in athletes and 
recreational participants of high-impact sports, including football, basketball, and soccer.37-39  
These cartilage injuries are frequently associated with other acute injuries, such as ligament or 
meniscal injuries, traumatic patellar dislocations, and osteochondral injuries.40-42  For example, 
articular cartilage defects are reported in up to 50% of athletes undergoing anterior cruciate 
ligament reconstruction.40,43  Besides acute injury, articular cartilage defects can develop in the 
high-impact athletic population from chronic pathologic joint-loading patterns, such as joint 
instability or misalignment.40-42  Repetitive intense joint loading is also observed in individuals 
with physically demanding occupations, including construction workers, metal workers, farmers, 
and pneumatic drill operators.  The consequence of either acute or chronic high-intensity loads is 
frequently cartilage degeneration, which may eventually lead to osteoarthritis.44-46 
With respect to obesity, the prevalent view has been that the mechanical effect of excess 
body weight is the direct cause of OA.  However, recent evidence suggests the systemic effects 
of metabolic factors associated with obesity are major contributors to OA pathogenesis.  Obesity 
is associated with an increased amount of adipose tissue, which is recognized as having potent 
endocrine activity and can give rise to chronic or low-grade inflammation.47,48  Leptin, a 
hormone produced mainly by adipose tissue, has been suggested to be an important factor in the 
link between OA and obesity.49  Elevated levels of leptin have been found in the synovial fluid in 
the knees of patients with OA, and have also been found to be expressed by OA chondrocytes.49  
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Increased amounts of fat—with elevated levels of arachidonic acid, a precursor to 
proinflammatory prostaglandin E2—have been identified in the bone marrow of patients with 
endstage OA.50  
Aging is the one of the most influential risk factors for developing OA.  While 7.6% of 
the 18-44 age group, and 29.8% of the 45-64 age group report doctor-diagnosed arthritis, 50% of 
persons aged 65 or older are diagnosed with arthritis.51  Although aging is generally not viewed 
as the cause of OA, aging events within articular chondrocytes may predispose the joint to 
damage when exposed to mechanical loads.  One of the most prominent age-related changes in 
chondrocytes is the exhibition of a senescent phenotype,52,53 which is the result of several factors 
including the accumulation of reactive oxygen species and advanced glycation endproducts.54-58  
Compared to a normal chondrocyte, senescent chondrocytes exhibit an impaired ability to 
respond to many mechanical and inflammatory insults to the cartilage matrix.59-63  Furthermore, 
protein secretion is altered in aging chondrocytes, demonstrated by a decrease in anabolic 
activity and increased production of pro-inflammatory cytokines and matrix degrading 
enzymes.64,65  Together, these events may make the articular cartilage matrix more susceptible to 
damage and lead to the onset of osteoarthritis.   
Etiology of RA 
The cause of RA is unknown and the pathogenic process may be initiated by several 
different events.  The initial stages of RA involve the initiation and establishment of 
autoimmunity, followed by an inflammatory response, angiogenesis to maintain the chronic 
inflammatory state, and tissue degradation of the joint.66  During the inflammatory process, the 
usually thin layer of synovial lining cells becomes greatly enlarged from the influx of monocytes 
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and lymphocytes from the circulation and from the local proliferation of fibroblasts, giving rise 
to a synovial hypertrophy called a pannus.67  This pannus formation contains activated B and T 
cells, plasma cells, mast cells, and particularly activated macrophages, which are involved in 
feeding back to perpetuate inflammation.  Central to this inflammatory response in the 
rheumatoid joint are high levels of inflammatory mediators, cytokines, and growth factors,68 
including TNF-α, IL-1β, IL-17, and transforming growth factor (TGF)-β.69   
 New blood vessels form following the inflammatory response, in a process known as 
angiogenesis, to maintain the inflammatory state by transporting nutrients to the developing 
pannus and inflammatory cells to sites of synovitis.70,71  Angiogenesis is regulated by many 
inducers and inhibitors, including acidic and basic fibroblast growth factors (bFGF), TGF, 
angiopoietin, placenta growth factor, and vascular endothelial growth factor (VEGF).72  VEGF, a 
dimeric glycoprotein which induces formation of new blood vessels and increases vascular 
permeability,72 is highly expressed in the synovial tissues of RA patients, and serum levels of 
VEGF correlate with RA disease activity.73  VEGF knockout mice show reduced RA disease 
activity and synovial angiogenesis in antigen-induced models of arthritis,74 suggesting that 
inhibiting VEGF-mediated angiogenesis is likely to suppress rheumatoid inflammation. 
Pathology of OA 
Articular cartilage, often considered the central focus of OA, plays an essential role in 
joint function and has a limited ability for self-repair.  The function of articular cartilage is to 
distribute mechanical loads across the entire joint surface and provide a nearly frictionless 
surface for joint articulation.75  In OA, the loss of articular cartilage leads to joint dysfunction, 
resulting in severe disability and pain.  Breakdown of the articular cartilage extracellular matrix 
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(ECM) involves destruction of its two primary components – type II collagen and proteoglycans.  
Degradation of the collagen fiber network and the loss of proteoglycans is one of the early events 
which precede the loss of cartilage tissue.75  Due to its avascular nature, articular cartilage 
exhibits a limited ability for repair, and damage to the cartilage matrix may continue to progress 
into more advanced lesions, resulting in osteoarthritis.   
The most common and generally accepted theory of the pathogenic mechanisms of 
primary OA involves the cumulative effects of continuous mechanical wear and tear on cartilage. 
In the model of biochemical cartilage degeneration, the initiation and progression of primary OA 
is linked to time/age-related modifications of resident cartilage matrix components, as well as 
age-dependent changes in the properties of newly synthesized and secreted matrix components, 
which together culminate in a structurally and functionally inferior cartilage matrix.46  It has 
been hypothesized that the pathophysiological process of OA can be described by several 
stages.76  At the beginning, the matrix–network degrades on a molecular level. The water content 
increases and the size of matrix molecules, namely aggrecan, decreases.  The structure of the 
collagen network is damaged, which leads to reduced stiffness of the cartilage.  In the second 
stage, chondrocytes try to compensate the damage by enhanced proliferation and metabolic 
activity.  Cell clusters surrounded by newly synthesized matrix molecules develop, which is 
referred to as cloning.  This condition can remain for several years. In stage three, the 
chondrocytes are not able to keep up their repair activity and a complete loss of the cartilage 
tissue is the consequence.77  
Pathways of cartilage destruction in OA include cell death, cell activation and abnormal 
differentiation of remaining chondrocytes, degradation of the extracellular matrix, and 
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production of inflammatory mediators.21  While the extracellular matrix of articular cartilage is 
the primary target of osteoarthritic cartilage degradation, chondrocytes have a pivotal role during 
osteoarthritis, as they are mainly responsible for the anabolic–catabolic balance required for 
matrix maintenance and tissue function.78  Chondrocytes may exhibit abnormalities during 
osteoarthritic cartilage degeneration, such as inappropriate activation of anabolic and catabolic 
activities, and alterations in cell number through processes like proliferation and (apoptotic) cell 
death.79 As the disease progresses, osteoarthritic chondrocytes can no longer maintain cartilage 
matrix integrity. 
There are many modes of interaction between the cells and the extracellular matrix. The 
cellular phenotype of chondrocytes is significantly influenced by the derangement or removal of 
the pericellular matrix or ECM to which these cells are adapted.80 The cells are affected by 
biomechanical stimuli that are transferred through the matrix as well as by the direct modulating 
function of specific matrix components. For example, fragments of fibronectin, one of the 
degraded matrix components typically found in OA joints, have been reported to induce severe 
matrix-degrading effects.81  Chondrocytes are also directly influenced by proteolytic enzymes 
and their inhibitors, which diffuse into the cartilage matrix from the surrounding synovial space.  
The ability of chondrocytes to maintain matrix homeostasis is severely impaired in osteoarthritic 
cartilage, in which the chondrocytes not only fail to compensate for matrix damage induced 
externally by factors such as mechanical stress or enzymatic degradation through synovial 
proteases, but also have a direct role in the degradation process. Osteoarthritic chondrocytes 
activate or upregulate the expression of many matrix-degrading proteases, such as the matrix 
metalloproteinases (MMPs), which are largely responsible for the breakdown of the collagenous 
and noncollagenous cartilage matrix components.78 The major collagen backbone (type II 
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collagen) is cleaved mainly by collagenase 3 (MMP-13) and further degraded by gelatinases 
(MMP-2 and MMP-9) as well as by other enzymes.82  As for the primary enzyme that degrades 
primarily aggrecan, the major proteoglycan present in cartilage tissue, studies using mouse 
models suggested that ADAMTS-5 (a disintegrin and metalloproteinase with thrombospondin 
motifs) might be the most important aggrecanase enzyme involved in cartilage destruction.83,84  
In OA, increased proteolytic activity is not sufficiently counterbalanced by an increase in 
chondrocyte anabolic activity.  Although there is an overall activation of anabolism in 
osteoarthritic chondrocytes, this increase in anabolic activity seems to decline and the anabolic 
defense reaction eventually fails.85  
Suppressing elevated levels of MMPs and ADAMTS in arthritis should be regarded to 
have substantial clinical benefit; however, a safe and effective inhibitor has not yet been 
developed.  MMP inhibitors used in clinical trials have so far failed to show significant efficacy 
in human diseases and in some instances resulted in side effects such as joint swelling and 
musculoskeletal pain.86  The side effects of MMP inhibitors were attributed largely to their lack 
of selectivity because metalloproteinases share structural similarities.87  Unintended MMP 
inhibition has been proven to be problematic, because aside from tissue breakdown, MMPs play 
critical roles in development, wound healing, and angiogenesis.88,89  For example, MMP-2 
knockout mice exhibited more severe clinical and histological arthritis than wild-type mice in an 
antigen-induced arthritis model90 and OA development was accelerated in MMP-3 knockout 
mice when compared to wild-type mice in a joint destabilization model.91   An alternative non-
invasive approach to suppressing MMP and ADAMTS activity may include moderate 
mechanical joint stimulation.  Reports have demonstrated the efficacy of physiologic joint 
loading such as passive motion therapy in arthritis.92-94  Furthermore, observations that moderate 
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loading can antagonize inflammatory cytokine-induced MMP upregulation indicate that such a 
strategy might be therapeutically useful.92,93 
Although chondrocytes can occasionally divide, adult articular cartilage is usually 
classified as a post-mitotic tissue with very little cellular turnover.95  Adult cartilage has no 
external cell supply from the vasculature, nor any sort of germinal cell layer to compensate for 
any form of cell death or damage that occurs in cartilage degeneration.  Consequently, any type 
of cell death results in serious disruption of tissue homeostasis.96  Morphological analysis of 
osteoarthritic cartilage has suggested the presence of empty lacunae in the matrix, which has lead 
to the long-standing assumption that cell death is a central feature in OA.97,98  However, 
apoptosis is presumably a rather rare event in osteoarthritic cartilage, as only a small fraction of 
apoptotic cells (<1%) are present in normal-aged or osteoarthritic cartilage at any given time 
point.95  By contrast, chondrocyte death in post-traumatic lesions seems to be a prominent 
issue.99,100  Although the extent and mechanism of cell death in OA is not fully understood, it is 
hypothesized that because the chondrocytes are either dead or have insufficient ability to control 
the anabolic–catabolic balance, tissue homeostasis is not well maintained. The majority of 
chondrocytes in osteoarthritic cartilage are viable, albeit, to a large extent, severely 
degenerated.78  
Current treatment strategies for arthritis 
There is currently no cure for OA.  The most successful intervention for OA continues to 
be total joint arthroplasty.  More than 300,000 total knee arthroplasties are performed each year 
within the United States, and that number is expected to increase significantly in the future.101  
While total joint replacements, to a degree restore, joint motion and function, there are a few 
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drawbacks.  First, articular cartilage is replaced with synthetic materials with a finite lifespan, 
necessitating a revision surgery if the patient outlives the functional lifespan of the implants.  
Secondly, this surgical procedure may have complications such as infection, deep vein 
thrombosis, and pulmonary embolus.  Finally, arthroplasty will not return patients to a pre-
arthritic level of function because there are no implants that can replicate the biomechanical 
characteristics of the native joint.102  For these reasons, it is important to understand the 
molecular events that lead to the development of OA, and identify potential targets to slow or 
halt disease progression. 
Current non-surgical OA treatment strategies mainly focus on mitigating the symptom of 
pain.5  Non-steroidal anti-inflammatory drugs (NSAIDs) are effective medications for the 
management of mild/moderate OA, due to their analgesic and anti-inflammatory properties, but 
have possible gastrointestinal, renal, and cardiovascular side effects.103  Intra-articular injections 
are also used in the clinical management of OA, particularly in joints that are easily accessible 
such as the knee, shoulder and ankle joints.  These injections are typically corticosteroid based or 
hyaluronic acid derivatives and may temporarily relieve pain and improve joint lubrication, but 
have not been clearly demonstrated to exert disease-modifying chondroprotective effects.103 
In fact, there are no disease modifying OA drugs (DMOADs) approved by the Food and 
Drug Administration or the European Medicines Agency.7 Due to the role upregulated 
MMPs/ADAMTS play in mediating the destructive process in arthritis, inhibitors for these 
proteolytic enzymes have been explored as therapeutic strategies to treat OA.  However, clinical 
trials so far have been met with limited success and resulted in side effects including 
musculoskeletal pain and inflammation.104-106  These adverse effects have been mainly attributed 
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to the lack of selectivity of these inhibitors.  Matrix metalloproteinases share structural 
similarities and are susceptible to regulation by broad-spectrum inhibitors.87  Poor selectivity is 
problematic because in addition to matrix remodeling, MMPs/ADAMTS play important roles in 
wound healing, angiogenesis, development, morphogenesis, and bone remodeling.88,89  Recent 
attempts at developing anti-catabolic drugs have focused on compounds with more selective 
profiles and are in early phase development.7  Clearly, pharmacologic solutions for treating OA 
need to define the correct molecular targets and ensure proper modulation of these targets. 
1.4. Mechanical loading and joint health 
 In addition to pharmacologic treatment of OA, non-pharmacologic therapies such as 
aerobic exercise and strength training are commonly prescribed, and have been reported to exert 
protective effects on the joint.  A Cochrane Review of 32 clinical trials comparing land-based 
therapeutic exercise (i.e. muscle strengthening, aerobics, manual therapy) to a non-exercise 
group found that exercise treatment resulted in moderate improvements in pain and physical 
function.107  Although clinical trials evaluating the effect of exercise on joint structure in OA 
patients are limited, preliminary results from these studies are promising.  A 4 month exercise 
program consisting of aerobic and weight-bearing exercises resulted in increased proteoglycan 
content in the articular cartilage of OA subjects.10  Strength training, compared to range of 
motion exercises for 30 months decreased the mean rate of joint space narrowing, but the 
difference was not statistically significant.11  Together, while the evidence report that moderate 
levels of physical activity improve symptoms of OA and may also exert chondroprotective 
effects, these mechanisms are not well understood. 
Non-physiologic joint loading  
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Although joints maintain homeostasis within a physiological range of mechanical 
loading, both reduced loading and overloading have catabolic effects, particularly for the 
cartilaginous components.  Damage to the knee articular cartilage surfaces are frequently 
observed in athletes and recreational participants of high-impact sports, including football, 
basketball, and soccer.37-39  Articular cartilage damage can also develop from chronic 
pathological joint-loading patterns, such as joint instability or misalignment.40-42  These articular 
cartilage injuries, as a consequence of either acute or chronic high-intensity loads, will frequently 
result in cartilage degeneration, which may eventually lead to osteoarthritis.44,45 
Experimental studies show that mechanical overloading can directly damage the cartilage 
extracellular matrix and shift the balance in chondrocytes to favor catabolic activity over 
anabolism.  While direct measurements of in vivo cartilage-on-cartilage contact stresses due to 
overuse in human joints have not been made, experimental evidence suggests a range of non-
physiological loading intensities.  There appears to be a critical threshold of 15-20 megapascals 
(MPa) for cell death and collagen damage due to a single impact load in bovine cartilage 
explants.108  In another study on bovine cartilage explants, chondrocyte apoptosis occurred at 
peak stresses as low as 4.5 MPa and increased with peak stress in a dose-dependent manner, 
while degradation of the collagen matrix occurred in the 7 to 12 MPa range,109 suggesting 
chondrocyte apoptosis may precede cartilage matrix damage.  In addition to peak stress, strain 
rate appears to be an important parameter implicated in cartilage damage.  Bovine cartilage 
explants compressed at a strain rate of 0.01 s-1 to a final strain of 50% showed in no measurable 
effect on biosynthetic activity or mechanical functionality (compressive and shear stiffness) in 
chondrocytes, although peak stresses reached 12 MPa,110 a stress high enough to cause injurious 
effects such as cell death.109  However, compression at higher strain rates (0.1 and 1 s-1), 
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resulting in peak stresses of about 18 and 23 MPa, reduced total protein biosynthesis and 
compressive and shear stiffness,110 suggesting that an increase in peak stress and strain rate is 
associated with increased injury.  Consistent with these results, high strain rates were reported to 
result in significant matrix fluid pressurization and impact-like surface cracking with cell death 
near the superficial zone  in bovine osteochondral explants.111  Studies also found that repetitive 
impact loading of 5 MPa at 0.3Hz induces collagen network damage and chondrocyte necrosis 
and apoptosis,112,113 suggesting that impact damage is cumulative.  Taken together, the data 
indicate that high levels of peak stress, high strain rates, and long-term injurious mechanical 
loading are usually correlated with deleterious effects on cartilage.  However, caution must be 
used when extrapolating these in vitro results to the in vivo situation.  Indenters used in these 
experiments are likely to cause large stress amplitudes and gradients at the location of impact, 
while in normally congruent articular joints, these stresses may be limited due a more even 
distribution of force.113  Therefore, the range of non-physiological load intensities in vivo should 
be greater than those reported in these in vitro studies.     
Similarly to overuse, reduced loading, occurring as a result of spinal cord injuries,114 
secondary to treatments for acute musculoskeletal injury,115 or from joint diseases such as 
arthritis,116 also results in articular cartilage degradation.  In vivo studies demonstrate that 
prolonged joint immobilization causes degradation of the cartilage matrix, characterized by 
fibrillation, ulceration, and erosion.117,118  Spinal cord injury patients report articular cartilage 
atrophy at a rate greater than that in age-associated osteoarthritis.119  Even during short-term 
reduced loading conditions (e.g. 7 weeks of partial weight bearing), a significant degree of 
cartilage thinning is reported in all compartments of the knee, although no cartilage lesions are 
observed.120   
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Cartilage damage from joint overuse and prolonged disuse is often irreversible due to the 
avascular nature of articular cartilage, which prevents a physiological inflammatory response.121-
123  Therefore, spontaneous repair of cartilage is limited, often resulting in biochemical and 
metabolic changes resembling early osteoarthritis, such as an accumulation of degradative 
enzymes and cytokines, disruption of collagen ultrastructure, increased hydration, and fissuring 
of the articular surface.124 
Moderate loading of healthy joints 
While reduced loading and overloading both cause cartilage degradation, moderate levels 
of activity maintain normal cartilage integrity.  Physiologic mechanical stimulation of the 
articular cartilage generates biochemical signals which increase the anabolic activity of the 
chondrocytes.125-127  Numerous in vitro studies have found increases in proteoglycan synthesis, 
collagen II expression, and cell proliferation after dynamic stimulation of chondrocytes in 
cartilage explants, 3D and monolayer cultures.126-129  Cyclic pressure-induced strain increased 
expressions of aggrecan and superficial zone protein in monolayer cultures130,131 and hydrostatic 
pressure in bovine cartilage explants loading increased both proteoglycan production and 
aggrecan mRNA synthesis.132,133   
Mechanical loading and arthritis 
It has been shown that moderate exercise may protect against cartilage degradation in 
animals that spontaneously develop OA.  Hamsters which ran 6-11 km/day maintained normal 
cartilage integrity while their sedentary counterparts developed fibrillation, pitting, and fissuring 
in the articular cartilage during this 3-month study.134  Normal cage activity rats with a 
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surgically-induced model of OA showed more macroscopic and histologic cartilage degradation 
when compared to exercised OA rats which ran 30 cm/s for 30 minutes for 28 days.135   
In humans, moderate recreational physical exercise is associated with a decreased risk of 
severe knee OA, suggesting that exercise has a protective effect against developing cartilage 
degradation.136  Furthermore, moderate joint loading may improve joint health and function in 
OA.10  Accumulating studies have demonstrated the effectiveness of non-drug treatment 
modalities, e.g., exercise and physical activity, as an adjunct to drug therapy in patients with OA 
and RA.137  Consequently, clinical practice guidelines developed to aid health practitioners in 
treating osteoarthritis recommend exercise therapy to reduce pain and improve joint function, 
based largely on the results of large randomized controlled trials evaluating exercise.138-142 
Clinical studies have shown that in RA, moderate exercise has systemic anti-
inflammatory effects by reducing disease activity.143  In vitro studies have provided evidence for 
a direct mechanosensitive mechanism on joint tissues.  Mechanical strain in synoviocytes 
decreases expression of prostaglandin-E2 (PGE2),144 an inflammatory mediator, and strain and 
shear both decreased the expressions of MMP-1 and -13 in RA synoviocytes.145,146  Furthermore, 
chondrocytes exposed to moderate levels of intermittent hydrostatic pressure inhibited IL-1β-
induced matrix degradation.147   
1.5. CITED2 
CBP/p300 Interacting Transactivator with ED-rich tail 2 (CITED2), a transcriptional co-
regulator, has been suggested to play a role in cartilage matrix homeostasis by suppressing 
proteolytic enzyme expression.148  CITED2 was originally cloned and shown to be inducible by 
various stimuli including cytokines, serum growth factors, lipopolysaccharide and hypoxia.149,150  
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CITED2 encodes a 28-kDa nuclear protein, and is present in a variety of cell types.150  During 
early development, CITED2 is widely expressed in both embryonic and extraembryonic cells, 
and is involved in regulation of cell proliferation and embryonic development.151  Loss of 
CITED2 was shown to result in senescence of cultured fibroblasts,152 while studies with 
CITED2-/- animals revealed roles in many different developmental processes, including the 
establishment of left-right body axis, and development of cardiac, neural, liver and lung 
tissues.151,153   
As a co-transcriptional regulator, CITED2 does not possess intrinsic DNA binding 
activity.  Instead, it functions as a context dependent transcriptional co-activator or co-repressor 
via interactions with other proteins.149,154  It has been shown that CITED2 acts as a co-activator 
transcription factors such as Lhx2, TFAP2, PPARα, PPARγ, and Smad 2 through, at least in part, 
the recruitment of CBP/p300, to act as a positive regulator of transcription.  On the other hand, 
CITED2 can also negatively regulate the activation of target genes by competing with 
transcription factors for binding to factors such as p300.  Such a mechanism was established in 
hypoxia response, where CITED2 downregulated HIF-1α-induced transactivation by competing 
with HIF-1α for binding to p300 via the CH1 domain.149  
That CITED2 is able to exert a wide range of regulatory roles in numerous cellular 
processes such as cell proliferation and embryonic development is mainly due to the ubiquity of 
p300 as a transcriptional co-regulator.149  By binding to p300 via the CH1 domain, CITED2 may 
interact, and likely compete, with a multitude of transcription factors including HIF-1α, Ets-1, 
NFκB, RXRα, STAT2, MDM2, and p53.155  Since both CITED2 and these other CH1 domain 
binding proteins are differentially expressed in various tissue and cell types, CITED2 can act in a 
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tissue and stimulus-dependent manner. Therefore, the regulatory roles played by CITED2 should 
be understood through its interaction with these function-associated proteins.   
 Because CITED2 is ubiquitously expressed and regulated by a wide range of stimuli, its 
effects vary considerably depending on the nature of the signal and of the cell type. For example, 
in chondrocytes, TGF-β induces CITED2 expression, which is consistent with the known role of 
TGF-β in downregulating MMP-1 in those cells.148  However, in MDA-MB-231 breast cancer 
cells, TGF-β downregulates CITED2 at the post-translational level.156  Similarly, upregulation of 
CITED2 under moderate intensities of mechanical loading in chondrocytes leads to 
downregulation of MMP-1 and MMP-13, but CITED2 knockdown in SW480 colon cancer cells 
results in a mild downregulation of MMP-1.157,158 
While CITED2 interacts with a wide range of transcriptional regulators, its own 
expression is responsive to several stimuli.  The ability of CITED2 to respond to a multitude of 
stimuli may be explained by the presence of regulatory elements such as Sp1, STAT, and NF-κB 
binding sites in the CITED2 promoter.159  The Sp1 transcription factor-binding site has 
previously been identified to be responsive to shear stress and promote gene expression.160   The 
deletion and site-directed mutations of the Ets-1 and Sp1 site upstream of the start codon are 
critical for CITED2 expression in fibroblasts.  Gel mobility shift and supershift assays performed 
with Rat1 nuclear extracts identified nucleoprotein complexes binding to the Ets-1 site and the 
Sp1 site.  In Drosophila SL2 cells, which lack the Sp and Ets family of transcription factors, 
expression of Sp1, Sp3, and Ets-1 or Elf-1 functionally stimulated CITED2 promoter activity in a 
synergistic manner.161   
Role of CITED2 in Mechanotransduction and MMP Downregulation 
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CITED2 was considered a likely mediator of mechanically-induced MMP suppression 
since it was known to antagonize transcriptional regulators like Ets-1, which have several 
binding sites within MMP promoter regions.162  Therefore, Yokota et al. used an immortalized 
human chondrocyte cell line C28/I2163 to investigate whether CITED2 was responsive to 
mechanical stimuli, and if so, could mediate shear-mediated downregulation of MMP-1 and 
MMP-13.148  CITED2 expression at the mRNA and protein levels was found to be inducible by 
moderate flow shear.  Expression was maximal at 5 dyn/cm2 and basal levels of expression were 
found at 0, 10, and 20 dyn/cm2.  In contrast, mRNA and protein expression and enzyme activities 
of MMP-1 and MMP-13 were upregulated at 0, 10, and 20 dyn/cm2 but were suppressed at 5 
dyn/cm2.148  Consistent with these findings, CITED2 expression was recently found to be 
inversely related to the expression of MMPs 2, 3, 9 and 13 in fractured bone in a rat mandibular 
osteotomy model.  Furthermore, overexpression of CITED2 in osteoblasts inhibited the 
expression and activity of MMP-2, -3, -9, and -13.164  Taken together, these data provide 
evidence that CITED2 is a mechanical stimuli responsive gene, and its inverse relationship with 
MMPs suggests it may play a regulatory role in load-driven MMP downregulation. 
To determine the relationship between load-induced CITED2 expression and MMP 
downregulation, loss-of-function and gain-of-function approaches were used.  Transfecting 
antisense CITED2 plasmids into chondrocytes abolished the loading-mediated downregulation of 
MMP-1, suggesting that CITED2 is required by load-driven MMP downregulation.  
Overexpression of CITED2 in chondrocytes reduced the basal level of MMP-1 expression under 
regular culture conditions, and protected cells from IL-1β-induced upregulation of MMP-1 and 
MMP-13.148 
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To elucidate the mechanism of MMP downregulation by CITED2, co-
immunoprecipitation with p300 specific antibody was used to identify potential regulatory 
proteins in p300 binding protein complexes. This approach was based on the understanding that 
CITED2 is not a DNA binding protein, and its role in MMP regulation has to be based on its 
interaction with DNA binding transcription factors of MMPs, either directly or via their co-
regulators such as CBP/p300.  Ets-1 was chosen as a primary target since CITED2 and Ets-1 are 
known to interact with p300, and Ets-1 is a DNA binding protein which can transactivate MMPs 
with p300 as a co-factor.162  C28/I2 chondrocytes were treated with moderate shear at 5 dyn/cm2 
or high intensity shear at 20 dyn/cm2.  Nuclear extracts were prepared and incubated with 
antibody specific for p300 to immunoprecipitate p300 protein complexes. Western blotting 
identified equal amounts of p300 in control and treated extracts.  In control cells, no p300-Ets-1 
or p300-CITED2 complexes were detectable.  In contrast, p300-CITED2 complexes were 
identified in cells exposed to flow shear at 5 dyn/cm2 and p300-ETS-1 complexes were detected 
in cells under 20 dyn/cm2.148  This study supports the hypothesis that CITED2 may mediate the 
mechanical loading-induced downregulation of MMP by competing with MMP transactivator 
Ets-1 for limiting amounts of co-factor p300 protein. 
Ets-1 proteins comprise a highly conserved family of transcription factors that share a 
unique DNA binding domain, the Ets domain.162  The Ets domain specifically recognizes DNA 
sequences that contain a GGAA/T core element.165  Ets-1 is a transcription factor that binds to 
MMP-1 and other MMP promoter regions.162  The Ets domain also serves as p300 CH1 binding 
domain, recruiting p300 as a co-factor in the transactivation of MMPs.  The Ets-1 activation 
domain or C-domain, is located between amino acids 130–242 and contains a high content of 
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acidic residues.  It is essential for Ets-1 to activate transcription and is also necessary for the 
interaction of Ets-1 with p300.162   
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Chapter 2 – Hypothesis and Specific Aims 
 Mechanical loading has been recognized as the most important factor for cartilage 
homeostasis.  It contributes critically to maintaining joint tissue homeostasis, especially cartilage 
integrity, and may cause cartilage degradation depending on the intensity, frequency, and 
duration of loading and form of mechanical loading (e.g. compression, fluid shear, strain, etc.).  
Cartilage homeostasis is maintained by balancing anabolic and catabolic activities.  Imbalance 
between anabolic activity and catabolic activity, especially overactivated catabolic activities in 
cases such as overloading, post-trauma, or aging, induces high levels of pro-inflammatory 
cytokines and high levels of proteolytic enzymes such as matrix metalloproteinases (MMPs), a 
predominant enzyme family that degrades components of the cartilage extracellular matrix.  In 
contrast, dynamic moderate loading not only enhances anabolic activities such as production of 
collagen and aggrecan, the two major matrix components, but also exerts anti-inflammatory 
activities.  It has also been reported that dynamic moderate loading such as intermittent 
hydrostatic pressure (IHP) suppresses expression and activity of MMP-1, -3, and -13 in 
chondrocytes, both in vitro and in vivo.  However, how dynamic moderate loading suppresses 
MMP expression is largely unknown.  Yokota et al. demonstrated that moderate intensities of 
flow shear (5 dyn/cm2) increased CITED2 mRNA and protein levels, and down-regulated MMP-
1 and MMP-13 in chondrocytes.  Antisense CITED2 plasmids prevented the shear-induced 
down-regulation of MMP expression, while overexpression of CITED2 repressed MMP-1 and 
MMP-13 mRNA and protein levels.   
These findings led to the hypothesis that CITED2 mediates a mechanical pathway in 
chondroprotection; appropriate levels of CITED2 are critical for cartilage integrity; and 
24 
 
restoration, or increasing levels of CITED2 exerts efficacy in prevention and treatment for 
cartilage degradation in arthritis. 
Objectives:  The overall objective is to determine and characterize the role of CITED2 as a 
mechanical inducible transcriptional regulator, identify the novel CITED2-mediated mechanical 
sensitive pathway in the downregulation of MMPs, and test the potential of CITED2 as a target 
for the prevention and treatment of cartilage degradation in arthritis.   Accordingly, four specific 
aims are proposed: 
Specifically, in Chapter 3 (Specific Aim 1), we will determine whether CITED2 
predominately responds to dynamic moderate loading and represses MMPs that are critical for 
cartilage integrity in chondrocytes.  The study will focus on the gene expression response of 
CITED2 to intermittent hydrostatic pressure (IHP), the most relevant mechanical loading 
modality articular cartilage experiences under various loading parameters (e.g. intensity, 
duration, post-loading time), and determine the role of CITED2 in mediating the mechanical 
regulation of MMPs.   
In Chapter 4 (Specific Aim 2), we will identify the CITED2-mediated mechanical 
signaling pathway that is required for the moderate loading-induced downregulation of MMPs.  
This study will focus on the role of CITED2 with its co-activator p300 and MMP transactivator 
Ets-1 in regulating MMP expression, and the pathway / signaling molecules that mediate 
loading-induced transactivation of CITED2.   
In Chapter 5 (Specific Aim 3), we will determine whether CITED2 is required for 
cartilage integrity maintenance by determining whether CITED2 is a causal factor for cartilage 
degradation in human specimens and mouse surgical and genetic models.   
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In Chapter 6 (Specific Aim 4), we will conduct a proof-of-concept study that CITED2 is 
a target for chondroprotection by examining the efficacy of CITED2 in slowing or preventing 
cartilage degradation via a) intra-articular gene transfer and b) pharmacologically via small 
molecule epigallocatechin gallate (EGCG), a compound extracted from green tea that activates 
CITED2, using two animal models of cartilage degradation: destabilization of the medial 
meniscus (DMM) and collagen-induced arthritis (CIA). 
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Chapter 3 – Biomechanical response of CITED2 and role of CITED2 in loading-induced 
downregulation of MMPs 
Abstract 
Mechanical loading is a critical regulator of cartilage homeostasis.  While both reduced 
loading and overloading lead to cartilage degradation, loading at moderate intensities is required 
for the maintenance of the cartilage matrix.  The molecular mechanisms which mediate these 
loading responses are not well understood.  CITED2 has been previously identified as 
transcriptional regulator which is induced by moderate intensities of flow shear, and mediates the 
loading-induced downregulation of MMP-1 and MMP-13.  In this study, we examined the 
mechanobiologic response of CITED2 to mechanical loading in vitro and in vivo. In vitro, we 
determined the effects on chondrocytes of intermittent hydrostatic pressure (IHP), which is 
considered the predominant mechanical force chondrocytes experience in vivo.  CITED2 
expression was induced by moderate intensities of IHP, at a range of 1.0 to 5.0 MPa, and peaked 
at 2.5MPa, when assessed at the mRNA and protein levels in chondrocytes after 1hr of loading at 
1Hz for 1hr.  CITED2 expression was induced with 15 minutes of IHP, peaked after 3 hours of 
loading, and started declining after 6 hours of loading.  The loading-induced response for 
CITED2 was transient; CITED2 levels peaked at 3 hours after loading, was elevated until at least 
12 hours, and returned to basal levels 24 hours after loading.  IHP loading at the range of 1.0 to 
7.5 MPa for 1 hr caused the decrease in multiple MMPs, such as MMP-2, -3, and -13, and was 
inversely correlated with the CITED2 response at both the mRNA and protein levels under all 
the tested loading regimes.  The data suggest a role of CITED2 in mediated the loading-induced 
downregulation of MMPs, which was further supported by the following evidence: 1) 
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overexpression of CITED2 in chondrocytes mimicked moderate IHP-induced suppression of 
MMPs in the presence or absence of IL-1β; 2) Moderate treadmill running (10m/min, 1hr, 0º 
incline) suppressed MMP-1, -2, -3, and -13 expression in wild-type mice, but this 
downregulation was not observed in CITED2+/- mice.  The response level of CITED2 may vary 
depending on the type of load, which may be critical in developing a CITED2 activation-based 
chondroprotection therapies based on mechanical loading.   
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Introduction 
 Mechanical loading is considered to be a critical regulator of skeletal homeostasis.2,166,167  
Mechanical loading induces the complex interaction of musculoskeletal tissues including bone, 
articular cartilage, and ligaments/tendons.  These mechanical stimuli can be categorized as 
beneficial for tissue development and maintenance, or detrimental, which can result in tissue 
breakdown and cause joint diseases such as osteoarthritis (OA).   
Articular cartilage functions as a nearly frictionless bearing surface while uniformly 
transferring loads on underlying bone preventing high stress concentrations. Cartilage consists of 
one cell type, the chondrocyte, embedded in an extracellular matrix of mainly type II collagen 
and proteoglycans.  Cartilage responds to mechanical loading in an intensity-dependent manner. 
Acute or chronic high-intensity loads, as seen in athletes participating in high-impact 
sports such as soccer, football, and basketball, often predispose the joint to OA.40-42  Joint 
injuries, such as anterior cruciate ligament (ACL) tears, similarly increase contact forces in the 
knee, and result in degradative changes such as chondral softening and fracture.168,169  Reduced 
joint loading also creates catabolic responses within articular cartilage.114,115  Animal models of 
reduced loading report that a decrease in mechanical stimuli leads to atrophy of the tissue,170-173 
and ultimately erosion of the articular cartilage.117,118  In humans, reduced loading in the form of 
partial weight bearing for 7 weeks results in significant cartilage thinning in the knee articular 
cartilage120 and spinal cord injury patients exhibit a rate of cartilage atrophy greater than that 
reported in age-associated osteoarthritis.119   
While reduced loading and overloading both cause cartilage degradation, moderate levels 
of activity maintain cartilage homeostasis.  Moderate loading of the articular cartilage generates 
mechanical signals that increase the synthetic activities of the chondrocyte while suppressing its 
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catabolic actions.125-127  In humans, exercise at moderate intensities is associated with a 
decreased risk of severe knee OA, suggesting that physical activity has a protective effect against 
developing cartilage degradation.136  However, the mechanisms underlying the beneficial effects 
of mechanical loading on cartilage integrity are not well understood.   
Cartilage degradation, or breakdown of the cartilage extracellular matrix (ECM), involves 
a variety of degradative enzymes, many of which are matrix metalloproteinases (MMPs).86,174  
The human genome has 24 MMP genes, including two duplicated MMP-23 genes.  The MMP 
family consists of the collagenases, (MMP-1, -8, and -13) which degrade collagens types I, II, 
and III, the gelatinases (MMP-2 and -9), which target denatured collagen, the stromelysins 
(MMP-3, -7, -10, and -11), which degrade several ECM proteins and are involved in proenzyme 
post-translational activation. 
 Our previous work has implicated CBP/p300-interacting transactivator with ED-rich tail 
2 (CITED2), as a mechanosensitive regulator of MMP-1 and -13.148  CITED2, a transcriptional 
regulator, is required for the suppression of MMP-1 and MMP-13 in response to moderate shear.  
In this study, we hypothesize that CITED2 mediates a chondroprotective signaling pathway in 
which moderate mechanical loading downregulates production of several MMPs in response to 
intermittent hydrostatic pressure, a loading stimulus used to mimic the chondrocyte mechanical 
environment.175  We will determine the loading duration and intensity-dependent nature of 
CITED2 and MMPs expression and the role of CITED2 in the mechanoregulation of MMPs 
through loss- and gain-of-function strategies 
. 
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Materials And Methods 
Intermittent hydrostatic pressure (IHP) loading  
C28/I2 cells, a human chondrocytic cell line,163 were cultured as high-density monolayers 
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum, 
100 μg/ml ascorbic acid, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C.158  Cells 
were starved in serum-free DMEM 18 hours prior to intermittent hydrostatic pressure (IHP) 
loading in a custom-made device.158  Culture plates were placed in 37ºC water bath in a stainless 
steel loading vessel within sterile, heat-sealed bags containing culture medium.   The loading 
vessel was maintained within a temperature controlled chamber set at 37ºC.  Pressure was 
generated within the pressure vessel interfaced with an Instron 8511 servo-hydraulic loading 
frame (Fig 3.1).  Air was evacuated from the system so the application of pressure was purely 
hydrostatic. Control cultures were maintained under identical conditions in heat-sealed bags in a 
37ºC water bath not subject to hydrostatic pressure.  After loading, cells were lysed for total 
RNA or protein isolation, for quantitative PCR or Western blot, respectively.   
 
Transfection of siRNA and plasmids 
To knockdown CITED2, C28/I2 cells were transfected with CITED2 siRNA (Santa Cruz, 
sc-35959) or a scrambled control (Santa Cruz, sc-37007) 24 hours prior to IHP.  To overexpress 
CITED2, C28/I2 cells were transfected with pcDNA3.1 plasmids carrying human CITED2 
cDNA as described.158  
 
RNA isolation and quantitative PCR 
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C28/I2 cells were extracted using the RNeasy mini kit (Qiagen, Valencia, CA) with 
DNase treatment according to manufacturer’s instructions.  RNA was quantified with a 
Nanodrop spectrophotometer (Thermo Fisher Scientific, Wilmington, DE), then reverse 
transcribed (RT) using oligo(dT) primers.  Two nanograms of total RNA were analyzed by real-
time quantitative PCR with SYBR Green (BioRad) to assess relative gene expression using the 2-
ΔΔCt method.176 Target gene expression was quantitated relative to housekeeping gene GAPDH.  
Gene (Accession number) Primer Sequence 
CITED2 (NM_001168388.2) F:  5’-GCGAAGCTGGGGAATAACAA-3’ 
R:  5’-ATGGTCTGCCATTTCCAGTCT-3’ 
MMP-1 (NM_001145938.1) F: 5’-TCTGGAAGGGCAAGGACTCT-3’ 
R: 5’-TCCGCTTTTCAACTTGCCTTT-3’ 
MMP-2 (NM_001127891.1) F: 5’-GAGTGCATGAACCAACCAGC-3’   
R: 5’-GGGCAGCCATAGAAGGTGTT-3’   
MMP-3 (NM_002422.3) F: 5’-TGTTCGTTTTCTCCTGCCTGT-3’ 
R: 5’-CAGCAGCCCATTTGAATGCC-3’ 
MMP-13 (NM_002427.3) F: 5’-GCACTTCCCACAGTGCCTAT-3’ 
R: 5’-AGTTCTTCCCTTGATGGCCG-3’ 
GAPDH (NM_001256799.2) F: 5’-AATGGGCAGCCGTTAGGAAA-3’ 
R: 5’-GCGCCCAATACGACCAAATC-3’ 
 
Western Blot 
Western blot was performed by using antibodies specific for MMP-1 (Abcam, ab52631), 
MMP-2 (Abcam, ab86607), MMP-3 (Abcam, ab18898), MMP-13 (Abcam, ab39012), CITED2 
(Santa Cruz, sc-21795) and Actin (ab3280).  Approximately 10 µg of the extracted proteins were 
separated by electrophoresis (SDS-PAGE) in a 10% polyacrylamide gel, and the separated 
proteins were transferred to Immun-Blot PVDF membranes (Bio-Rad, Hercules, CA).  
Membranes were incubated with primary antibodies followed by incubation with secondary 
antibodies conjugated to horseradish peroxidase (ECL Western blotting analysis system, GE Life 
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Sciences, Piscataway, NJ).  A mouse antibody specific for β-actin (Sigma-Aldrich, St. Louis, 
MO) was used as loading control. 
 
Treadmill running 
Cited2+/- carry one allele of Cited2, with the other allele excised and replaced with a neo 
cassette.177  These mice were received as a gift from Dr. Yu-Chung Yang.  Cited2+/- mice and 
wild-type littermates (male, 6 months old) were subjected to 1 hour of treadmill running (1 hour, 
10m/min, 0° incline) or regular cage activity.  Three hours after this loading regimen, the 
articular cartilage from the knee was harvested and flash frozen for RNA isolation.  Gene 
expression for Cited2, MMPs-1, -2, -3, and -13 were assessed by real-time PCR with GAPDH 
used as a housekeeping control. 
 
Statistical Analysis  
 Results are expressed as mean ± SD.  Statistical analysis was carried out using a one-way 
ANOVA and Tukey’s test for post hoc analysis with significance set at P < 0.05.   
 
Results 
Response of CITED2 and MMPs to IHP loading 
IHP induced biphasic changes in the expression of CITED2 and MMP-2, -3 and -13 in 
C28/I2 chondrocytes (Fig 3.2A). CITED2 expression by qPCR increased up to 7-fold at 2.5 
MPa, returning to basal levels at 7.5 MPa. In contrast, expression of MMP-2, -3, and -13 
exhibited biphasic decreases in expression over the same range of IHP. MMP-2 and -13 were 
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suppressed most strongly at 2.5 MPa IHP and returned to basal levels at 7.5 MPa, while MMP-3 
was less sensitive.  Maximal inhibition of MMP-3 was seen at 5.0 MPa, and expression remained 
significantly below control levels at the highest pressure tested (7.5 MPa).  Corresponding 
elevations in CITED2 and reductions in MMPs were also seen at the protein level by Western 
blotting (Fig. 3.2B).  Expression of all MMPs and CITED2 were inversely correlated, with 
correlation coefficients of -0.73, -0.53, and -0.85 for MMP-2, -3 and -13, respectively. 
CITED2 mRNA upregulation in response to continued exposure to 2.5 MPa IHP was 
rapid; 60% of maximal stimulation was observed after 15 minutes. A plateau of expression 
(values not significantly different from the 3 hour maximum value) was achieved by 1 hour and 
was sustained through 6 hours, although there appeared to be a trend of declining expression at 
the latest time point (Fig 3.3A, 3.3B).  Downregulation of MMP-2, -3, and -13 occurred over the 
same time interval, although significant reductions were in expression were not seen until 30 
minutes of IHP exposure, i.e. following the upregulation of CITED2 (Fig 3.3A, 3.3B).  A single 
3 hour exposure to IHP induced changes in CITED2 and MMP expression that persisted for up to 
12 hr or more, as assessed by real-time PCR and Western blot, respectively (Figs 3.4A and 
3.4B).  
 
CITED2 mediated loading-induced suppression of MMPs  
The inverse time and dose relationships between CITED2 and MMP expression in 
response to IHP suggested that the suppression of MMP expression by moderate loading may 
result through the actions of CITED2.  To test this possibility, we first suppressed CITED2 
expression in C28/I2 chondrocytes with siRNA and found that MMP expression in the absence 
of IHP was increased.  Moreover, moderate IHP loading (2.5 MPa, 1 hour) failed to suppress 
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MMP expression in chondrocytes treated with si-CITED2 (Fig 3.5A).  Suppression of MMPs in 
the absence of mechanical load was also dependent on the extent of CITED2 overexpression (Fig 
3.6A, B).  
Loading-induced MMP suppression reduced in Cited2+/- mice 
To determine whether the mechanical effect of moderate loading (treadmill running) 
would similarly affect expression of MMPs in vivo, and to test whether CITED2 mediates these 
loading-induced effects, wild-type and Cited2+/- mice were subjected to moderate treadmill 
running for 1 hour or allowed regular cage activity.  Without loading, Cited2+/- mice exhibited 
50% less Cited2 expression and elevated MMP expression (Fig 3.7).  One hour after this 
treadmill running, Cited2 gene expression was elevated and MMP expression was reduced in 
wild-type mice, but to a lesser extent in Cited2+/- mice (Fig 3.7).  
 
Discussion 
Presently, both resistance and gentle exercises are prescribed for rehabilitation of injured 
or arthritic knees.  However, the optimal duration and physical loading necessary for achieving 
the beneficial effects of exercise are unclear.  Defining a physical activity as “moderate or 
physiological” is a challenge because loading regimes involve many parameters such as 
intensity, frequency and duration, and a “moderate” physical activity for a particular individual 
might vary depending on an individual’s age, genetics, gender, and physical activity history.  
Therefore, identifying biomarkers associated with moderate loading may provide useful 
indicators for choosing the right type exercise/physical activity with a precise loading regime and 
therefore increase efficacy of mechanical-based therapies for cartilage protection and treatment.  
35 
 
We examined the response of CITED2, a transcriptional regulator induced by mechanical shear 
which exerts an anti-catabolic role by repressing MMP-1 and -13 expression and activity.148  In 
this study, we showed CITED2 was upregulated in response to moderate intensities of IHP, 
which was directly related to the downregulation of MMP-2, -3, and -13.  This suggests there is a 
moderate range of loading which is chondroprotective.  As CITED2 only responded to moderate 
mechanical loading, it is possible CITED2 expression may be utilized as a biomarker to define 
which physical activities may be considered “physiologic.”  We also examined the effect of 
loading duration, and post-loading time in response to moderate IHP.  The induction of CITED2 
and suppression of MMP expression plateaued after 1 hour of loading.  Furthermore, the up-
regulation of CITED2 was sustained until at least 12 hours after loading.  Together, this suggests, 
with regards to chondroprotection, that 1 hour of moderate physical activity once or twice a day 
may be sufficient to maintain an anti-catabolic environment within the articular cartilage.   
While chondrocytes in vivo experience many types of mechanical forces, such as shear, 
strain, and compression, we focused on intermittent hydrostatic pressure loading because it is the 
predominant force chondrocytes experience in vivo.178  The fact that CITED2 is responsive to 
multiple forms of mechanical loading supports the concept that CITED2 is a mechanically 
responsive regulator.   
In addition to the role CITED2 played in suppressing MMP-1 and -13 expressions, this 
study revealed CITED2 is also a transcriptional regulator for MMP-2, and -3.  MMP expression 
was reduced but not completely suppressed in response to moderate mechanical loading.  This 
form of MMP modulation may represent a more physiologic method of regulating MMP 
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expression in arthritis, in contrast to complete MMP suppression induced by MMP inhibitors 
tested in clinical trials.   
 The overexpression of CITED2 mimicked the anti-catabolic effects of moderate 
mechanical loading on MMP suppression, suggesting CITED2 may be a molecular target for 
chondroprotection to suppress excess catabolic activity in arthritis.  The activation of CITED2, 
by mechanical means may be a therapeutic strategy to slow or arrest cartilage degradation.  
However, the mechanisms through which mechanical loads transactivate CITED2 are not 
understood and require further elucidation. 
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Figures 
 
Fig 3.1.  Schematic of intermittent hydrostatic pressure loading device.  Cell culture plates sealed 
in sterile bags were loaded in a pressurized chamber interfaced to an Instron 8511 servo-
hydraulic loading frame. 
 
Figure 3.2.  Loading intensity-dependent induction of CITED2 and suppression of MMP 
expression.  (A) mRNA and (B) protein expression of CITED2 and MMP-2, -3, and -13, 1 hour 
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after intermittent hydrostatic pressure (IHP) loading at 1.0, 2.5, 5.0, and 7.5 MPa, at 1Hz for 1 
hour, in C28/I2 chondrocytes.  n=5/group.  *=p<0.05 compared to unloaded controls.   
 
Figure 3.3.  Time-dependent effects of IHP loading on CITED2 and MMP expression.  (A) 
mRNA and (B) protein expression of CITED2 and MMP-2, -3, and -13 after 1 hour of IHP 
loading for 0.25, 0.50, 1.0, 3.0, and 6.0 hours of IHP at 2.5MPa and 1Hz, in C28/I2 
chondrocytes.  n=5/group.  *=p<0.05 compared to unloaded controls.  
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Figure 3.4.  Post-loading effect of IHP on CITED2 and MMP expression.  (A) mRNA and (B) 
protein expression of CITED2 and MMP-2, -3, and -13 at 0.25, 0.5, 1, 3, 6, 12, and 24 hours 
after IHP for 3 hours at 2.5MPa and 1Hz.  n=5/group.  *=p<0.05 compared to unloaded controls.  
 
Figure 3.5. CITED2 is required for moderate IHP-induced suppression of MMPs (A) mRNA 
and (B) protein expression of MMP-2, -3, and -13 in chondrocytes treated with CITED2 siRNA 
with or without IHP (2.5MPa, 1Hz, 1hr).  n=5/group.  *=p<0.05 compared to unloaded controls. 
 
Figure 3.6. Overexpression of CITED2 mimics the effect of moderate IHP-induced suppression 
of MMPs.  (A) mRNA and (B) protein expression of MMP-2, -3, and -13 in chondrocytes 
transfected with plasmids carrying 0.1  or 1.0 μg of human CITED2 cDNA, or vector controls.  
n=5/group.  *=p<0.05 compared to untransfected controls. 
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 Figure 3.7.  Cited2+/- mice exhibited a reduced level of Cited2 and elevated levels of MMPs 
compared to age and gender-matched wild-type littermates. Effect of moderate treadmill running 
(10m/min, 1hr, 0° incline) on suppressing expression of MMP-1, -2, -3, and -13, which was 
observed in wild-type mice, was diminished in Cited2+/- mice.    n=3/group.  *=p<0.05. 
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Chapter 4 - Physiologic Loading Of Joints Prevents  
Cartilage Degradation Through CITED2 
Abstract 
Both overuse and disuse of joints upregulate matrix metalloproteinases (MMPs) in 
articular cartilage and cause tissue degradation; however, moderate (physiologic) loading 
maintains cartilage integrity. Here we test whether CITED2, a mechanosensitive transcriptional 
co-regulator, mediates this chondroprotective effect of moderate mechanical loading. In vivo, 
hindlimb immobilization of Sprague-Dawley rats upregulates MMP-1 and causes rapid, 
histologically detectable articular cartilage degradation. One hour of daily passive joint motion 
prevents these changes and upregulates articular cartilage CITED2. In vitro, moderate (2.5 MPa, 
1 Hz) intermittent hydrostatic pressure (IHP) treatment suppresses basal MMP-1 expression and 
upregulates CITED2 in human chondrocytes whereas high IHP (10 MPa) downregulates 
CITED2 and increases MMP-1. Competitive binding and transcription assays demonstrate that 
CITED2 suppresses MMP-1 expression by competing with MMP transactivator, Ets-1 for its co-
activator p300. Furthermore, CITED2 upregulation in vitro requires the p38δ isoform, which is 
specifically phosphorylated by moderate IHP.  Together, these studies identify a novel regulatory 
pathway involving CITED2 and p38δ, which may be critical for the maintenance of articular 
cartilage integrity under normal physical activity levels. 
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Introduction 
Mechanical loading is one of the most important environmental factors responsible for 
joint homeostasis and there is tremendous concern about how joint motion and load bearing may 
impact joint health.  Articular cartilage maintains its integrity throughout life under moderate 
loading conditions experienced during routine daily activity.  In contrast, when cartilage is 
subjected either to excessive or insufficient mechanical loading, degeneration occurs.  Exposure 
of joints to acute and chronic (repetitive) high-intensity loading eventually leads to osteoarthritis 
(OA).46,179  On the other hand, the absence of normal mechanical stimulation, as occurs in 
paralysis following spinal cord injury, can also cause articular cartilage breakdown through the 
induction of a similar catabolic response.171,180   To date, we have begun to define many of the 
cellular and molecular processes responsible for these catabolic changes.21 However, the 
mechanism through which moderate loads prevent cartilage degradation and maintain functional 
capacity remains unknown.   
Articular cartilage destruction results from the breakdown of extracellular matrix (ECM) 
constituents, primarily type II collagen and aggrecan, whose proteolysis are mediated by matrix 
metalloproteinases (MMPs) and a disintegrin-metallo proteinases with thrombo spondin motifs 
(ADAMTS), respectively. MMPs comprise a large family of structurally related endopeptidases 
and are considered to be the principal mediators of both normal ECM remodeling and pathologic 
degradation.181 Of the 26 MMPs identified, MMP 1, 8, and 13 represent the secreted neutral 
proteinases capable of cleaving type II collagen.181  MMPs 1 and 13 are highly expressed in the 
cartilage and synovium of OA and rheumatoid arthritis patients,182-185 though MMP-8 is not 
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appreciably elevated in OA.186 Other MMPs including MMPs 2, 3, and 9 have also been reported 
to play a role in the degradation of cartilage ECM.21,187 
 MMP expression and function are controlled, both positively and negatively, at multiple 
levels including transcription and enzyme activity (e.g. via inactivation by specific inhibitors like 
tissue inhibitors of metalloproteinases, or TIMPs).86  Upregulation of MMPs in response to 
mechanical stimuli has been documented in a wide range of tissues and cells,188 via multiple 
signal transduction pathways often involving members of MAP kinase families, e.g. p38 and 
p42/44,189 but much less is known about the downregulation of MMP expression by mechanical 
loading.  In a previous study, we showed that moderate levels of flow shear downregulated 
expression of MMP-1 and MMP-13 in human C28/I2 chondrocytes, and that this downregulation 
coincided with upregulation of the transcriptional regulator CITED2 (CBP/p300-interacting 
transactivator with ED-rich tail 2),148 suggesting that CITED2 may contribute to MMP regulation 
in chondrocytes.  In the present study we sought to define the role of CITED2 in the regulation 
of MMPs by focusing on MMP-1, a prototypical catabolic enzyme that cleaves type II collagen 
and is highly expressed in arthritic articular cartilage.183,190  We then determined whether 
CITED2 regulates other MMPs such as MMPs 2, 3, 13, through a similar mechanism as with 
MMP-1 using a strategy involving mutagenesis of the CITED2 functional motif and a ChIP 
assay. 
 
Materials And Methods 
Animal Experiments 
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 Male Sprague-Dawley rats (5-6 months old, 580 ± 35 g) were housed with access to food 
and water ad libitum.  All procedures were approved by the IACUC of Mount Sinai School of 
Medicine.  The right hind limbs were immobilized as previously described.191  Briefly, rats were 
anesthetized with isoflurane and were fitted with a cast made of steel mesh and cotton materials 
which fixed the knee in full flexion (115°).  Animals were either left immobilized for the 
duration of the experiment, released from casting for 1h under anesthesia (sham) or subjected to 
motion loading at a frequency of 2 cycles/minute with a range of motion between 65° and 115° 
using a custom-designed loading device.192  The in vivo loading device consisted of an animal 
bed and an anesthesia machine integrated into a custom-built knee joint motion/load apparatus, a 
linear actuator with micro-stepping driver and digital encoder, a magnetic goniometer for real-
time joint angle readout, a load cell for compressive load monitoring, a USB analog/digital I/O 
interface module, and LabView control panel (Fig 4.1).  The anesthetized animal was placed 
prone over an acrylic bed, and the right hind limb of the animal was placed in the knee joint 
apparatus.  The knee joint apparatus transformed the linear motion provided by the actuator into 
angular displacement at the knee joint.  The loading device had adjustable control of motion 
frequency and range of angular displacement via a linear actuator with 50 mm travel stroke 
(bipolar NEMA 13 Hybrid, Haydon Motion, Waterbury, CT) coupled to an incremental rotary 
encoder (E5S, US Digital Corp, Vancouver, WA).  After motion loading or release from 
immobilization under anesthesia (sham group), the rats were sacrificed or re-cast until the next 
motion loading session.  The short and extended protocols are described in the ‘Results’ section. 
In each protocol, a control group was allowed free cage activity throughout the experiment.  
Following sacrifice, cartilage from immobilized knee joints (distal femur, proximal tibia) was 
rapidly removed and prepared for MMP activity assays, histology or RNA isolation.   
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MMP activity assay 
Articular cartilage was dissected, flash-frozen in liquid nitrogen and stored at -80°C. 
MMP-1 activity was assayed by using the Senosolyte Plus 520 MMP-1 assay kit (Anaspec, 
Fremont, CA).  Frozen tissue samples were pulverized (Dismembrator, B Braun Biotech, 
Germany) in MMP activity assay buffer (Anaspec) containing 0.1% (vol/vol) Triton-X 100, and 
then centrifuged for 15 minutes at 10,000 g at 4°C.  The supernatant was added to a 96-well plate 
containing immobilized MMP-1 antibody in the presence of 4-aminophenylmercuric acetate 
(APMA) for 3 hours, and its proteolytic activity was measured by the 5-FAM/QXL 520 FRET 
peptide (Anaspec).  The fluorescence of 5-FAM (fluorophore) was quenched by QXL 520 in the 
intact FRET peptide.  Fluorescence signal was monitored at Ex/Em=490 nm/520 nm upon 
MMP-1 induced cleavage of the QXL FRET substrate.  Fluorescent intensity was measured 
using the SpectraMax M5 spectrofluorometer (Molecular Devices, Sunnyvale, CA).   
Immunohistochemistry and Safranin O staining 
Total knee joints were fixed in formalin, decalcified, paraffin-embedded and sectioned.  
For immunostaining, endogenous peroxidase activity was blocked with 3% (vol/vol) H2O2 for 5 
minutes. Tissues were incubated overnight at 4°C with either anti-CITED2 (1:300, Santa Cruz, 
Santa Cruz, CA), anti-MMP-1 (1:100, Abcam, Cambridge, MA), or Col2-3/4M (1:200, Ibex 
Pharmaceuticals, Canada),  followed by a 30 minute incubation with anti-mouse or anti-rabbit 
secondary antibody (Dako, Carpinteria, CA) and visualization with DAB chromagen for 3 
minutes.  Negative control sections were prepared using irrelevant isotype-matched antibodies in 
place of the primary antibody.  Safranin O-fast green staining was carried out to demonstrate 
glycosaminoglycans in the articular cartilage. 
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Cartilage explants, cell culture, and intermittent hydrostatic pressure loading 
Articular cartilage from the rat distal femur and proximal tibia were carefully separated 
from the underlying bone under a dissecting microscope.  The cartilage explants and C28/I2 cells 
(cultured as high-density monolayers) were each cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine serum, 100 μg/ml ascorbic acid, 100 
U/ml penicillin, and 100 μg/ml streptomycin at 37°C.193  Both the rat articular cartilage explants 
and C28/I2 cells were starved in serum-free DMEM 18 hours prior to intermittent hydrostatic 
pressure (IHP) loading in a custom-made device.194  After loading, cartilage explants pulverized 
in liquid nitrogen and C28/I2 cells were lysed for total RNA or protein isolation, for quantitative 
PCR or Western blot, respectively.   
Transfection of siRNA and plasmids 
C28/I2 cells were incubated with siRNA for CITED2 (Santa Cruz) or transfected with 
pcDNA3.1 plasmids constructed to encode cDNA sequences for wild-type (WT) human 
CITED2, Ets-1, or mutant forms of CITED2 and Ets-1 with selected sequences deleted using 
restriction enzyme digestion and PCR cloning strategies as described.148  In other studies, WT or 
mutated human CITED2 cDNA were co-transfected with either WT p300 or a dominant negative 
(DN) p300 form in which the CH1 domain was deleted to prevent CITED2-binding (Upstate 
Biotechnology, Lake Placid, NY).  
RNA isolation and quantitative PCR 
Total RNA from flash frozen articular cartilage or C28/I2 cells was extracted using the 
RNeasy mini kit (Qiagen, Valencia, CA) with DNase treatment according to manufacturer’s 
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instructions.  RNA was quantified with a Nanodrop spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE), then reverse transcribed (RT) using oligo(dT) primers.  Two 
nanograms of total RNA were analyzed by quantitative PCR with SYBR Green to assess relative 
gene expression, as well as GAPDH and β-actin as housekeepers.  PCR primers pairs used were: 
rat-MMP-1A, forward 5’- ACAGTTTCCCCGTGTTTCAG-3’, reverse 5’-
CCCACACCTAGGTTTCCTCA-3’; human-MMP1, forward 5’-
GGTGACACCAGTGACTGCAC-3’, reverse 5’-TCCACAAATGGTGGGTACAA-3’; 
rat/human-CITED2, forward 5’- TGCCGCCCAATGTCATAG-3’, reverse 5’-
CTGCTGTTTGCACACGAAG-3’; rat/human-GAPDH, forward 5’-
GAGGACCAGGTTGTCTCCTG-3’, reverse 5’-ATGTAGGCCATGAGGTCCAC-3’; 
rat/human-β-actin, forward 5’-TTGCTGACAGGATGCAGAAG-3’, reverse 5’-
ACATCTGCTGGAAGGTGGAC-3’.  Expression values of GAPDH and ß-actin for each 
treatment condition were averaged and used as a denominator to determine the relative 
expression of target genes using the 2-ΔΔCt method. 
Western Blot/Immunoprecipitation Assay 
Western blot was performed by using antibodies specific for MMP-1 (EMD Chemicals, 
Gibbstown, NJ), CITED2 (Santa Cruz). Ets-1 (Santa Cruz), and p300 (Upstate Biotechnology).  
Approximately 10 µg of the extracted proteins were separated by electrophoresis (SDS-PAGE) 
in a 10% polyacrylamide gel, and the separated proteins were transferred to Immun-Blot PVDF 
membranes (Bio-Rad, Hercules, CA).  Membranes were incubated with primary antibodies 
followed by incubation with secondary antibodies conjugated to horseradish peroxidase (ECL 
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Western blotting analysis system, GE Life Sciences, Piscataway, NJ).  A mouse antibody 
specific for β-actin (Sigma-Aldrich, St. Louis, MO) was used as loading control. 
For immunoprecipitation, 100 µg of nuclear extracts were mixed with 8 µg of p300-
specific antibody (Upstate Biotechnology) and incubated with gentle rocking at 4°C overnight.  
The immunocomplexes were captured by mixing with protein G-agarose beads for 2 h at 4°C.  
The collected agarose beads were washed four times with an ice-cold cell lysis buffer, and the 
precipitated proteins were eluted by boiling the beads for 5 min in the SDS sample buffer.  
Fractions of the supernatant were analyzed by SDS-PAGE and immunoblotting using antibodies 
against p300, CITED2, and Ets-1.  
Promoter Analysis and Luciferase Assay 
 A 510 bp region from the MMP-1 promoter (-468 to +42 relative to the transcription start 
site, GenBank M16567) was cloned by amplifying human genomic DNA by PCR and sub-
cloned into the pGL3-Basic Vector (Promega, Madison, WI) immediately upstream of the 
luciferase reporter gene.  Wild-type and serial deletions of the 5′ end of the CITED2 promoter 
region were generated in separate reactions and subcloned into pGL3-basic vector.  For the 
MMP-1 promoter assay, chondrocytes were transfected or co-transfected with MMP-1 promoter 
reporter construct, pcDNACITED2, pCMVp300 (Upstate Biotechnology), pKD-p300-v1 (p300 
siRNA), p300 siRNA scramble, and empty vector controls, and/or subjected to IHP loading (2.5 
MPa, 1 Hz, 1 hr).  For the CITED2 transactivation assay, the cells were transfected or co-
transfected with a CITED2 promoter reporter construct, pCMVp38δ WT, pCMVp38δ DN, 
pCMVp38α WT, pCMVp38α DN (Cell Biolabs Inc., San Diego, CA), p38δsiRNA (Ambion, 
Austin, TX), and/or subjected to IHP loading (2.5 MPa, 1 Hz, 1 hr).  For the CITED2 promoter 
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serial deletion analysis, wild type and deleted CITED2 promoter reporters were co-transfected 
with pCMVp38δ WT into chondrocytes.  DNA constructs were transfected into cells using 
Lipofectamine Plus Reagent (Life Technologies, Carlsbad, CA). For luciferase assay, cells were 
harvested in Passive Lysis Buffer (Promega).  Luciferase activity in the cell lysates was 
determined using the Dual-Luciferase Reporter Assay System (Promega).  All firefly luciferase 
values were normalized for transfection efficiency using the pRL-TK, Renilla-luciferase value.   
Peptide Competition Assay 
 Ets-1 displacement from GST-p300 CH1 (aa302-423) domain by the synthetic CITED2 
transactivation domain (TAD) peptide (aa224-255), and CITED2 TAD displacement from the 
GST-p300 CH1 domain by Ets-1 TAD peptide (aa153-210) were measured by an ELISA-based 
peptide competition assay, as previously described.195  Briefly, increasing amounts of CITED2 or 
Ets-1 TAD peptide were added to immobilized biotinylated Ets-1 peptide or biotinylated 
CITED2 TAD peptide, respectively.  A constant amount of GST-p300 CH1 was then added.  
Bound GST-p300 CH1 was quantified by time-resolved fluorescence using europium-labeled 
anti-GST antibody (Perkin Elmer, Waltham, MA).  Mean half-maximal inhibitor concentration 
(IC50) values were calculated for twenty-five separate experiments after fitting data using a non-
linear regression (GraphPad Prism, La Jolla, CA). 
Kinase Assay 
 The phosphorylation of p38 isoforms were conducted using a nonisotopic p38 MAPK 
assay kit (Cell Signaling, Danvers, MA) as previously described.196  Briefly, total cell lysates 
were prepared from chondrocytes and equal amounts of total protein (100 μg) were precipitated 
using p38α or p38δ MAPK antibody, respectively.  The activities of precipitated kinases were 
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then allowed to phosphorylate the p38 substrate, ATF2, in the presence of ATP.  
Phosphorylation of ATF2 was analyzed by immunoblotting with an antibody specific for 
Phospho-ATF2.  The expression of p38α or p38δ was confirmed by immunoblotting with the 
isoform-specific antibody.  
Chromatin immunoprecipitation (ChIP)   
C28/I2 human chondrocytes were treated with IL-1β (10ng/ml) to induce MMP 
expression, with or without CITED2 transfection.  ChIP was performed using a commercial kit 
following manufacturer’s instructions (USB). Cell lystes were immunopreciptated with anti-Ets-
1 (Santa Cruz), and PCR performed using primers specific for Ets-1 binding sites (GGAA/T) in 
MMP promoter regions. 
Statistical Analysis  
 Results are expressed as mean ± SD.  Statistical analysis was carried out using a one-way 
ANOVA and Tukey’s test for post hoc analysis with significance set at P < 0.05.   
 
Results 
CITED2 Induction in Articular Cartilage in vivo is Associated With MMP-1 Downregulation 
and Anti-catabolic Effects of Joint Motion 
To test whether CITED2 mediates the protective effects of physiologic joint motion on 
cartilage, we first determined the relationship between of CITED2 and MMP-1 expression under 
different mechanical loading regimens.  Two protocols were used.  In the first “short” protocol, 
four groups of rats were treated as follows: (1) no immobilization and no passive motion (Con); 
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(2) continuous immobilization for 6 hours (Im); (3) immobilization for 6 hours interrupted by 1-
hour passive motion (Pm); and (4) immobilization for 6 hours interrupted by a 1-hour release 
from the cast under anesthesia, with no passive motion (Sh) (Fig. 4.2A).   
Quantitative PCR (qPCR) analysis of articular cartilage samples dissected immediately 
after the immobilization period revealed that MMP-1 was upregulated in the immobilization-
only group (Fig. 4.2B).  The upregulation of MMP-1 was accompanied by a decline in CITED2 
mRNA (Fig. 4.2C).  In contrast, passive motion loading applied for 1 hour in the midst of the 6-
hour immobilization period completely reversed these changes (Figs. 4.2B and 4.2C).  
Importantly, simply removing the immobilization stimulus for 1 hour without accompanying 
passive motion (sham group), did not reverse the immobilization-induced upregulation of MMP-
1.    
We next extended the immobilization protocol to 7 days and inserted a 1-hour passive 
motion loading period each day (“extended” protocol) (Fig. 4.2D).  qPCR analysis (Figs 4.2E 
and 4.2F) revealed that immobilization stimulated MMP-1 while attenuating CITED2 
expression, but both of these changes were prevented upon passive motion loading.  We also 
measured the activity of MMP-1 and found that it mirrored MMP-1 mRNA levels under all 
conditions examined (Fig. 4.2G).   
 Histological examination of distal femoral articular cartilage revealed evidence of tissue 
degradation in immobilized rats, and also indicated that these changes were largely prevented by 
passive motion loading (Fig. 4.2H).  In particular, immobilization led to decreased Safranin O 
staining (indicating reduced proteoglycan content) in the superficial zone of articular cartilage; 
this decrease was accompanied by increases in the number of MMP-1-positive cells, stronger 
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staining for denatured type II collagen in the superficial and middle zones of the articular 
cartilage, and reduction in the number of cells with positive staining for CITED2.  By contrast, 
passive motion loading of immobilized limbs prevented loss of proteoglycans, limited the 
increases in immunohistochemically detectable MMP-1 and denatured type II collagen, and also 
increased the number of cells staining positive for CITED2 (Fig. 4.2H, middle and bottom 
panels).  Taken together, these results indicate that in vivo moderate loading suppresses the 
catabolic response to immobilization by inducing CITED2 and downregulating MMP-1.  
CITED2 is Required for Moderate Loading-induced Downregulation of MMP-1 
In order to assess the regulatory role of CITED2 in MMP-1 expression in vitro and ex 
vivo, intermittent hydrostatic pressure (IHP), which is thought to best mimic the loading 
environment experienced by articular cartilage in vivo 178, was utilized to mechanically stimulate 
freshly recovered rat cartilage explants or cultured chondrocytes.  As shown in Figures 4.3A and 
4.3B, the application of 2.5 and 5.0 MPa, pressures consistent with those experienced by joints 
during walking,185 caused a profound increase in CITED2 and a decrease in MMP-1 mRNA 
expression in rat articular cartilage explants.  Parallel in vitro studies with chondrocytes showed 
qualitatively similar results to those with cartilage explants, namely elevation in CITED2 mRNA 
and reduction in MMP-1 mRNA seen best at 2.5 MPa (Figs. 4.3C and 4.3D), as well as 
corresponding changes in protein expression on Western blotting (Fig. 4.3E).   
To determine whether CITED2 was indeed required for MMP-1 downregulation in 
response to mechanical stimuli, we used CITED2 loss and gain of function strategies.  A modest, 
but significant, increase in MMP-1 mRNA was noted when CITED2 was suppressed by siRNA 
knockdown in the basal state (Fig. 4.3F).  As expected, loading lowered MMP-1 mRNA, but 
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importantly, failed to do so in si-CITED2 transfected cells (Fig. 4.3F).  Western blotting showed 
an effective reduction of CITED2 protein in the si-CITED2 transfectants, and also demonstrated 
their resistance to load-induced MMP-1 downregulation (Fig. 4.3G).  Consistently, moderate 
loading, as well as CITED2 overexpression, also dramatically inhibited the expression of MMP-
1 induced by IL-1β, a key mediator of cartilage degradation in both OA and rheumatoid arthritis 
197 (Fig. 4.3H).  This load-induced suppression of MMP-1 was again abolished in si-CITED2 
transfected cells (Fig. 4.3H).  These experiments provide clear evidence that, at least in vitro, the 
upregulation of CITED2 is required for the load-induced attenuation of MMP-1.   
To further demonstrate the critical involvement of CITED2 in the moderate loading-
induced downregulation of MMP-1, modulation of MMP-1 at the transcriptional level by 
CITED2 was examined by transactivation assays.  CITED2 is a transcriptional regulator that 
does not bind directly to DNA promoter regions, but functions by interacting with other 
transcription factors or cofactors such as p300.198  For this reason, chondrocytes were co-
transfected with a 2.3 kb MMP-1 promoter-luciferase construct and either empty vector or 
constructs containing CITED2, p300, or si-p300, and the promoter activity was measured using a 
luciferase assay.  In certain conditions, cells were subjected to moderate loading at 2.5 MPa, 1 
Hz, for 1 hr.  As shown in Figure 4.4, cells transfected with empty vector or si-scramble 
displayed potent luciferase activity (in agreement with the MMP-1 mRNA results in Fig. 4.3), 
and the activity level was further stimulated by p300 overexpression.  In contrast, the MMP-1 
transactivation was substantially reduced in all groups of cells overexpressing CITED2, and the 
suppressive effect of CITED2 was comparable to those with either loading (2.5 MPa) or p300 
knockdown (Fig. 4.4).  These findings indicate that MMP-1 transcription is directly mediated by 
CITED2 and p300.   
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CITED2 Downregulates MMP-1 by Competing with Ets-1 for p300 Binding 
 We next took further steps to dissect the detailed molecular events surrounding the 
CITED2 regulation of MMP-1 expression.  The transcriptional co-regulator p300 is the principal 
binding partner of both CITED2 and MMP-1 transactivator Ets-1.149,195,199,200  We speculated that 
CITED2 may function to downregulate MMP-1 by competing with Ets-1 for p300 binding.  To 
test this hypothesis, we characterized the p300 complexes in cells with altered expression of 
CITED2 by immunoprecipitation assays.  As shown in Figure 4.5A, the formation of CITED2-
p300 complexes due to either loading (which upregulated CITED2) or CITED2 overexpression 
was accompanied by complete displacement of Ets-1 from its p300 binding site.  Conversely, 
suppression of CITED2 by transfection with si-CITED2 enhanced Ets-1 binding to p300 (Fig. 
4.5A).  These results support our premise that the p300-CITED2 complex formed upon loading 
is responsible for the effects of CITED2 on MMP-1 expression.    
The direct competition between CITED2 and Ets-1 for binding to p300 was supported by 
two additional observations.  First, an examination of a dominant-negative (DN) p300 lacking 
the CH1 domain that binds to CITED2 and Ets-1 indicated that p300 was absolutely required for 
the regulation of MMP-1 by CITED2 or Ets-1.  As expected, loading at 2.5 MPa reduced MMP-
1 and increased CITED2 expression without affecting p300, both in untransfected and vector-
transfected chondrocytes.  In contrast, overexpression of wild-type p300, which led to increased 
complex formation between p300 and Ets-1, blocked the load-induced attenuation of MMP-1 
without altering CITED2 levels (Fig. 4.5B).  However, p300-DN was unable to correct the load-
induced downregulation of MMP-1. Overexpression of CITED2 under these conditions 
mimicked the effects of loading (Fig. 4.5C).  Second, bound GST-p300 CH1 quantified by time-
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resolved fluorescence measurements of a Europium-labeled anti-GST antibody in ELISA-based 
competition assays revealed a subtle difference between the half-maximal inhibitory (IC50) 
concentrations for reduction of the Ets-1-p300 complex by CITED2 (0.58 nM) and of the 
CITED2-p300 complex by Ets-1 (0.90 nM) (Figs. 4.5D and 4.5E).  This difference suggests a 
potential chondroprotective mechanism that p300, under physiological conditions, may exhibit a 
slight preference for binding to its partner, CITED2, over its catabolic co-regulator Ets-1. 
To identify specific regions within the binding domains of CITED2 and Ets-1 required 
for MMP-1 regulation, we carried out a series of transfection experiments using deletions and 
point mutations introduced into each molecule (Fig. 4.6A).  In the first set of experiments, we 
treated chondrocytes transfected with wild-type or mutant CITED2 with IL-1β and examined 
MMP-1 mRNA and protein expression by PCR and Western blotting, respectively.  We found 
that the CITED2 fragment containing amino acids (aa) 224 to 256 was both necessary and 
sufficient for MMP-1 downregulation, whereas a CITED2 fragment lacking this region (i.e. 
fragment 1-223) did not (Fig. 4.6B).  More specifically, EPEE, a mutation of the LPEL motif 
found within the 224-256 amino acid region, completely abolished the downregulation of MMP-
1 expression, suggesting that LPEL was critical for load-induced MMP-1 regulation. 
Co-transfection of chondrocytes with wild-type CITED2 and mutated forms of Ets-1 
(Fig. 4.6C) showed that overexpression of CITED2 suppressed IL-1β-induced expression of 
MMP-1 and that overexpression of wild-type Ets-1 partially reversed the MMP-1 suppression 
caused by CITED2.  However, this rescue was abolished in the transfectants overexpressing Ets-
1 fragments in which the transactivation domain (TAD, aa 135-243) was removed either by 
truncation beyond aa 153 and 165, respectively, or through its deletion, as in the fragments ∆166-
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194 and ∆178-210 (Fig. 4.6D).  Most importantly, however, the fragment 153-210 fully reversed 
the effects of CITED2 overexpression, suggesting that the p300-binding domain of Ets-1, which 
competes with CITED2, is indeed the critical component of the TAD. 
p38δ Activation Mediates the Loading-induced Transactivation of CITED2 
 Finally, we determined the upstream signal(s) necessary for moderate mechanical loads 
to induce CITED2 expression.  Amongst several known candidates that act as potential 
mechanotransducers, the MAP kinases, particularly p38, have received much attention.201,202  
However, the roles played by individual p38 isoforms (p38α, p38β, p38γ, p38δ) in cartilage 
mechanotransduction have not been investigated.  Moderate loads of 2.5 MPa, which upregulate 
CITED2 and downregulate MMP-1 (Figs. 4.7A and 4.7B), did not stimulate phosphorylation of 
p38α but specifically stimulated the phosphorylation of a p38δ (Fig. 4.7C).  In contrast, 
chondrocytes loaded at 10 MPa results in the phosphorylation of p38α (Fig. 4.7C), which 
coincides with the upregulation of MMP-1 (Fig. 4.7B), a change that typifies a catabolic 
response to non-physiological loads.  We therefore explored how p38δ regulates CITED2 
expression in response to moderate loading by examining the transactivation of the 3.3 kb 
CITED2 promoter.  Promoter-reporter assays using luciferase constructs transfected into 
chondrocytes confirmed the stimulation of CITED2 transactivation by both loading and p38δ 
overexpression, proving that p38δ is upstream of CITED2 and downstream of loading (Fig. 
4.7D).  Furthermore, this response was abolished by dominant-negative p38δ and si-p38δ.  
Analysis of CITED2 promoter responsiveness to p38δ by means of progressive deletion 
constructs showed that removal of the NF-κB-binding site did not appreciably reduce promoter 
transactivation (Fig. 4.7E).  Deletion of the HIF-1α response element in the (-940) CITED2 
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promoter region attenuated transactivation by ~50% (Fig. 4.7E).  However, while removal of one 
Sp1 site in the -2300-bp CITED2 fragment produced no change in transactivation, the 
subsequent deletion of three further Sp1 sites almost completely abolished promoter 
responsiveness to p38δ (Fig. 4.7E).  Together, this data suggests that the effect of p38δ on 
CITED2 is, at least in part, mediated by HIF-1α and Sp1.   
Competing with Ets-1 for p300 is a common mechanism for CITED2 regulation of MMPs 1, 2, 
3, and 13  
Our results suggest CITED2 may regulate MMP expression by competing with Ets-1 for 
p300 binding.  As MMP-2, -3, and -13 also carry Ets-1 binding sites on their promoter, we tested 
that CITED2 regulates multiple MMPs through this Ets-1-p300 mechanism. Towards this end, 
we constructed and transfected the CITED2 motif (LPEL) which binds to p300 and a mutant 
motif unable to bind to p300 (EPEE), in chondrocytes (Fig 4.8A).  Overexpression of the 
mutated CITED2 motif, in contrast to the wild-type motif, was unable to downregulate MMP 
expression and activity when overexpressed in C28I2 cells, suggesting that CITED2 suppression 
of MMP expression is mediated through p300 binding (Fig 4.8B).  To provide further evidence 
and the precise regulatory mechanism that CITED2 binding to p300 prevents Ets-1 mediated 
transcription of MMPs, ChIP assays were performed using an antibody against Ets-1.  IL-1β, 
which stimulates MMP expression in C28/I2 chondrocytes, increased binding of Ets-1 to at least 
one putative Ets-1 binding site on the promoter regions of MMPs 1, 2, 3, and 13 (Fig 4.8C).  
However, these protein-DNA bindings were significantly decreased when CITED2 was 
overexpressed in IL-1β treated cells (Fig 4.8C). These data indicate that CITED2 downregulates 
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the transactivation of MMPs 2, 3, and 13 by preventing Ets-1 from forming productive 
transcriptional complexes with p300, similar to that observed with MMP-1.  
 
Discussion 
 The idea that musculoskeletal tissue integrity is best maintained at moderate 
(physiologic) levels of mechanical loading has long been appreciated.  In muscle and bone, for 
example, repair of minor tissue damage from overuse entails breakdown and removal of the 
damaged tissue and replacement with newly formed matrix.203,204  On the other hand, tissue 
breakdown also occurs as a result of loading insufficiency, resulting in muscle atrophy205 and 
osteopenia or osteoporosis.206  While an understanding of the molecular mechanisms that 
transduce mechanical stimuli into increases in bone and muscle mass is emerging, less is known 
of how mechanical stimuli generated by joint movement, and the frequency and intensity of such 
loads, help to maintain cartilage integrity. Accumulating clinical evidence indicates that, in 
contrast to excessive or inadequate loads, continuous passive motion along with other forms of 
physiological joint loading is necessary for proper joint maintenance, and joint motion can 
protect cartilage from cartilage degradation 92,93,147.  In this study, we show for the first time that 
physiologically relevant passive loading of normal joints prevents cartilage degradation through 
the upregulation of CITED2 using the p38δ pathway.   
         Matrix metalloproteinases (MMPs) are proteolytic enzymes responsible for the destruction 
of articular cartilage. This study focused on a single MMP (MMP-1) and on its transcriptional 
control by CITED2.  MMP-1 was selected for this study as a prototypical catabolic enzyme 
because it directly cleaves type II collagen and is highly expressed in arthritic articular 
59 
 
cartilage.183,190  Moreover, since MMP-1 has only been identified recently in mice and rats,207,208 
the role of MMP-1 is less understood in rodent models.  Using a mutagenesis strategy of the 
CITED2 p300 binding domain and ChIP assay, we further demonstrated that the CITED2 p300 
binding ability is required and sufficient to suppress multiple MMPs including MMPs 1, 2, 3, 
and 13 by preventing Ets-1 binding to MMP promoter sites to trigger transcription of MMPs, and 
therefore repressing their expression. 
Our study provides several lines of evidence that CITED2 is essential in order to mediate 
the transcriptional suppression of MMP-1 by moderate hydrostatic pressure loading, and 
elucidate mechanistic features of this novel pathway.  1) Analysis of CITED2 loss and gain of 
function revealed that under moderate levels of intermittent hydrostatic pressure, si-CITED2 
abolished the reduction in MMP-1 expression and forced overexpression of CITED2 mimicked 
the effects of moderate loading by downregulating MMP-1.  2) CITED2 competed with a MMP 
transactivator, Ets-1, and displaced it from the p300-Ets-1 complex to reduce MMP-1 
transactivation.  3) The CITED2 nucleotide region encoding the fragment between amino acids 
224 to 270 was absolutely required and sufficient to downregulate MMP-1.  4) CITED2 
suppressed MMP-1 promoter activation in a process requiring p300.  Taken together, these 
observations strongly support our hypothesis that CITED2 mediates a chondroprotective 
signaling pathway by competing with Ets-1 for p300 binding to downregulate MMP-1 
expression.  That our results in vivo and in vitro were in excellent agreement with respect to the 
inverse relationship between expression of CITED2 and MMP-1 argue strongly that the 
mechanistic relationships we established in vitro are likely to hold in vivo. 
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 The proposed mechanism of MMP-1 regulation by CITED2, involving competition with 
Ets-1 for binding to p300, was consistent with expectations based on published binding 
characteristics of CITED2 and HIF-1α for p300.195  Interestingly, however, the competition 
binding studies indicated a slightly greater affinity of p300 for CITED2 than for Ets-1.  To the 
extent that these relationships translate to in vivo circumstances, the result suggests that this 
potential regulatory switching mechanism may be slightly biased toward suppression, rather than 
activation, of MMP transcription.  Such a bias might be useful to prevent overaggressive 
catabolic responses to changes in the mechanical environment. 
While our results demonstrated direct transcriptional regulation of MMP-1 by CITED2 in 
chondrocytes, it is likely that additional regulatory mechanisms may also operate, particularly in 
vivo. Virtually all cell types present in joint tissues (cartilage, bone, synovium) are 
mechanoresponsive.148,209-211  Furthermore, mechanical stimulation is known to alter the 
production of, as well as response to, cytokines known to regulate MMP expression, including 
IL-1β and TNF-α 92,93,147.   
Another novel finding of this study was that the mechanosensitive upregulation of 
CITED2, which occurred in response to moderate levels of mechanical loading in vitro and in 
vivo, was associated with the selective activation of a specific isoform of p38, p38δ.  Members of 
the p38 MAP kinase family are activated in response to mechanical stresses and a wide range of 
chemical stimuli,202,212 and have been implicated in the upregulation of MMPs.213  We have 
observed that high levels of loading led to neither phosphorylation of p38δ nor CITED2 
upregulation.  This may partially explain why CITED2 is functional only under moderate loading 
with regards to the regulation of MMP expression.  Conversely, excessive loading induced 
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MMP-1 and phosphorylation of p38α, suggesting that the latter is likely involved in the 
regulation of MMP-1.  Together, these data indicate that distinct members of the p38 family can 
act within the same cell population to promote and to suppress MMP-based matrix breakdown 
depending on the mechanical loading environment. 
 In summary, we have identified a novel CITED2-mediated pathway in which CITED2, 
induced by moderate loads through the activation of p38δ, suppresses MMP-1 transcription by 
displacing transactivator Ets-1 from co-activator p300. The identification of this CITED2 
pathway as a means to regulate MMP expression in cartilage not only provides a molecular basis 
for the prevention of cartilage degradation by physiologic loads, but also offers the possibility 
that this pathway could be exploited therapeutically in diseases like arthritis.   
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Figures 
 
Figure 4.1. In vivo motion knee joint motion loading device.  The schematic diagram of the in 
vivo device (left). Experimental setup with a rat undergoing the motion and loading protocol 
(right). 
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 Figure 4.2.  Passive motion loading prevents cartilage degradation.  (A) Schematic 
representation of the Short Protocol, where the rat hind limb is immobilized for six hours 
interrupted by 1-hour of passive motion or release from immobilization under anesthesia, or the 
(D) Extended Protocol, where the rat limb is immobilized for 7 days with or without a 1-hour per 
day passive motion protocol.  (B, E) qPCR showing fold-change in mRNA levels of MMP-1 or 
(C, F) CITED2, and (G) MMP-1 (enzyme) activity after immobilization (Im), passive motion 
loading (Pm), sham treatment (Sh), or no treatment (Con).  (H) Safranin O staining and 
immunohistochemical localization of MMP-1, type II collagen denaturation (Col2-3/4M 
antibody), and CITED2 in articular cartilage from rats undergoing the Extended Protocol.  
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Statistics: One way ANOVA and Tukey’s post hoc test, *p < 0.05 versus control, n=5 rats per 
group.  Scale bar = 100 µm. 
 
Figure 4.3.  CITED2 is required for load-induced downregulation of MMP-1.  (A, B) qPCR 
showing the effect of intermittent hydrostatic pressure loads (IHP, MPa as shown, 1 Hz, 1 hour) 
applied to articular cartilage explants (n=5 rats per group) or to (C, D) chondrocytes on CITED2 
and MMP-1 mRNA expression and (E) CITED2 and MMP-1 protein expression detected by 
Western blot.  (F, H) qPCR and (G) Western blots showing, respectively, the effect of 
transfecting chondrocytes with pcDNA3.1-CITED2 or small interfering RNAs for CITED2 (si-
CITED2) or scrambled RNA (si-Scramble) on MMP-1 mRNA and protein expression in 
response to IHP (2.5 MPa, 1Hz, 1 hour) in the absence or presence of IL-1β.  *p < 0.05, versus 
control, in triplicate.  
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 Figure 4.4.  Direct effects of CITED2 and p300 on MMP-1 promoter transactivation.  Effect of 
co-transfecting chondrocytes with CITED2, Ets-1 or p300 in various combinations (shown) 
with/without siRNA for p300 (si-p300) or IHP (2.5 MPa, 1 Hz, 1 hour) on MMP-1 promoter 
activity in luciferase assays.  *p < 0.05, versus vector transfected cells, in triplicate.   
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 Figure 4.5.  CITED2 competes with Ets-1 for p300 binding.  (A) Immunoprecipitation with anti-
p300 antibody and Western blot (WB) with either anti-CITED2 or anti-Ets-1 antibodies to reveal 
protein-protein interactions between Ets-1, CITED2 and p300.  (B) qPCR showing the effects of 
overexpressing p300 or dominant-negative p300 (p300-DN) on the relative expression of MMP-
1, CITED2 and p300 in response to IHP (2.5 MPa, 1Hz, 1 hour) or (C) co-transfection with wild 
type CITED2 without IHP.  Mean half-maximal inhibitor concentrations (IC50, nM) for (D) 
CITED2 on Ets-1-p300 or (E) Ets-1 on CITED2-p300.   
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 Figure 4.6.  CITED2 regulates MMP-1 through specific motif.  (A) Effect of transfecting 
chondrocytes with plasmids encoding either wild-type (WT) CITED2 or CITED2 deleted, 
truncated, or point mutants on (B) MMP-1 and CITED2 mRNA (PCR) and/or protein (Western 
blot) expression in the presence of IL-1β.  Abbrev: CR – conserved region; ∆srj – CITED2 wild-
type with deletion of 39-amino acid serine-glycine rich junction; EPEE – mutated LPEL (aa243-
246) motif.  (C) Effect of co-transfecting wild-type Ets-1 or Ets-1 deleted or truncated mutants 
with CITED2 on (D) MMP-1 and CITED2 mRNA (PCR) and/or protein (Western blot) 
expression in the presence of IL-1β.   
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 Figure 4.7.  MAP Kinase p38δ is the upstream mediator of CITED2 in response to moderate 
loading.  (A) qPCR showing the effect of IHP (MPa as shown, 1 Hz, 1 hour) on the expression of 
CITED2 and (B) MMP-1.  (C) Western blot showing p38δ and p38α activation, measured as 
phosphorylation of the p38 substrate, ATF2.  (D) Luciferase activity in chondrocytes transfected 
with the CITED2 promoter-reporter construct after application of IHP (2.5 MPa, 1 Hz, 1 hour), 
or co-transfection with wild-type or dominant negative p38δ or p38α, or (E) with sequential 
deletion constructs of CITED2 co-transfected with p38δ.  *p < 0.05 versus control, wild-type, or 
previous deletion construct, in triplicate.   
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 Figure 4.8.  CITED2 mimics suppression of MMPs 1, 2, 3, and 13 in chondrocytes in the 
presence of IL-1β by wild-type CITED2 but not functional domain deleted CITED2.  (A)   
Transfection of wild-type CITED2 but not EPEE mutant suppressed MMP gene expression and 
activity in chondrocytes in the presence of IL-1β.  Upper panel:  Wild-type and CITED2 mutant 
constructs.  EPEE is a mutation of the LPEL motif found within the 224-256 amino acid region.   
(B) Western blot showed overexpression of wild-type and mutant CITED2.  (C) ChIP analysis 
with Ets-1 binding sites on MMP promoters shows that increased Ets-1 binding after IL-1β 
treatment was prevented with CITED2 overexpression.  n=3/group.  *=p<0.05. 
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Chapter 5 – CITED2 is required for cartilage homeostasis: deletion of CITED2 in mice 
leads to osteoarthritis 
Abstract 
Joint diseases such as osteoarthritis (OA) are a leading cause of adult disability and 
characterized by progressive cartilage destruction and damage to the integrity of bone and other 
joint tissues.  The pathogenesis of OA is not well understood, nor is there an effective treatment 
to cure or even slow its progression.   CITED2 (Cbp/p300 Interacting Transactivator with ED 
rich tail 2), is a transcriptional regulator which plays critical roles in suppressing expression of 
enzymes which directly cleave the cartilage extracellular matrix, such as matrix 
metalloproteinases (MMPs-1, -13).  In previous chapters, we demonstrated that CITED2 is a 
mediator required for the loading-induced downregulation of MMPs.  CITED2 downregulated 
MMP expression by competing with MMP transactivator Ets-1 for binding to co-factor p300.  
Reduction of CITED2 expression was associated with immobilization-caused cartilage 
degradation, suggesting a critical role for CITED2 in maintaining cartilage integrity and 
homeostasis.  In this study, we tested whether deficiency of CITED2 is a casual factor for 
cartilage degradation and arthritic diseases.  We found that reductions of CITED2 expression 
were associated with cartilage degradation in human and mouse OA cartilage, compared to age- 
and gender-matched non-OA controls.  Experimental knockdown of CITED2 in adult mice, by 
intra-articular gene transfer of CITED2 shRNA, or by genetic deletion in an inducible, cartilage-
specific knockout mouse model, led to early OA-like cartilage pathology.  Furthermore, the 
knockdown of CITED2 accelerated the progression of post-traumatic OA in the destabilization 
of the medial meniscus (DMM) mouse model, compared to wild-type DMM mice.  We find that 
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CITED2 plays its role in maintaining cartilage integrity, at least in part, by modulating 
expression of MMP-13 and ADAMTS5, which are considered the predominant proteolytic 
enzymes in OA pathogenesis.  Restoring CITED2 expression in OA tissues may be a therapeutic 
strategy for arresting or slowing OA progression. 
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Introduction   
Previous studies have demonstrated that CITED2 is a mechanically responsive 
transcriptional regulator required to mediate cellular responses to mechanical loading that protect 
against cartilage degradation.148,158  Of notice, while dynamic moderate loading induced CITED2 
expression and suppressed MMPs, immobilization (reduced loading) resulted in cartilage 
degradation and was associated with reduced levels of CITED2.  Furthermore, knockdown of 
CITED2 in vitro, abolished the loading-induced MMP downregulation, and caused an elevation 
of MMP expression above its basal level.  These studies allow us to ask the following questions:  
Do reduced levels of CITED2 a) correlate with severity of established OA and b) increase 
susceptibility of developing OA under given circumstances?  What are the mechanisms through 
which CITED2 mediates chondroprotection?   
To address these questions, we first investigated whether there was an association 
between CITED2 expression and the extent of cartilage degradation characterized by OARSI 
score in human OA cartilage.  We then evaluated then expression level of CITED2 during the 
initiation and progression of OA in post-traumatic OA mice.  We further examined whether 
knockdown of CITED2 in cartilage can cause OA-like pathology.  We examined the effect of 
specifically deleting CITED2 in adult mice, and examined the deficiency of CITED2 involved in 
OA development in post-traumatic mice using the DMM model. 
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Methods   
Human OA samples - Human OA specimens were collected from patients undergoing total knee 
or hip replacement surgery with written consent in accordance to an IRB-approved protocol 
(n=8, avg. age=70±7.3 yrs).  Age- and gender-matched non-OA cartilage was obtained from 
post-mortem patients without history of joint diseases.  Cartilage was dissected, fixed in 10% 
formalin, and embedded in paraffin for sectioning. 
Induction of osteoarthritis in mice - Destabilization of the medial meniscus (DMM) in 5-6 
month-old male C57BL/6 mice was carried out by transecting the medial meniscotibial ligament 
(MMTL), (n=6).  A 3 mm longitudinal incision over the distal patella to proximal tibial plateau. 
The joint capsule immediately medial to the patellar tendon was incised with a # 15 blade and 
the joint capsule opened with micro-iris scissors. Blunt dissection of the fat pad over the 
intercondylar area was then performed to expose either the intercondylar region, providing 
visualization of or the meniscotibial ligament of the medial meniscus. Mild hemorrhage from the 
fat pad upon blunt dissection was controlled by pressure from absorption spears.  The medial 
meniscotibial ligament (MMTL) anchors the medial meniscus (MM) to the tibial plateau. The fat 
pad over the cranial horn of the medial meniscus was dissected with Jewelers forceps. The 
MMTL was identified running from the cranial horn of the medial meniscus laterally onto the 
anterior tibial plateau. Sectioning of medial meniscotibial ligament was performed with a # 11 
blade, gave destabilization of the medial meniscus (DMM).  Control joints involved a sham 
surgery in which the ligament was visualized but not transected. The joint capsule was closed 
with a continuous 8-0 tapered Vicryl suture and the subcutaneous layer with 7-0 cutting Vicryl. 
The skin was closed by the application of tissue adhesive.  
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CITED2 suppression in vivo - Intra-articular injections of CITED2 shRNA (10 mg/10 uL PBS) 
were performed followed by electroporation every 7 days in a separate set of 8- to 10-wks-old 
male C57BL/6 mice. Contralateral controls received injections of PBS only followed by 
electroporation (n=3).   
Cited2 conditional knockout mice - Col2a1-Cre/ERT x Cited2flf mice were generated by crossing 
Cited2-floxed mice with Col2a1-Cre/ERT mice 214,215.  Genotyping confirms mice with Cre and 
two Cited2-floxed alleles (Figure 1).  Daily intraperitoneal injection of tamoxifen 
(1mg/10g/mouse/day for 5 days) in skeletally mature, 5-6 month-old male mice resulted in 
knockdown of the Cited2 gene in articular chondrocytes when assessed at 8 weeks.   
Immunohistochemistry and Safranin O staining -   Sections were incubated overnight at 4°C with 
anti-NITEGE (cleaved aggrecan), anti-Col2 3/4M (denatured type II collagen), anti-CITED2, 
anti-MMP-13 anti-ADAMTS5, or irrelevant isotype-matched antibodies as negative controls, 
followed by a secondary antibody and visualization with DAB chromagen. Histological scoring 
was performed by Safranin O/Fast green.   
 
Results   
Loss of CITED2 correlates with cartilage degradation in human OA and DMM mice.   
In human OA cartilage samples, “healthy,” regions with strong Safranin O staining were 
correlated with high levels of CITED2 expression, and low levels of aggrecan cleavage and type 
II collagen denaturation.  On the other hand, areas of cartilage destruction, indicated by local loss 
of Safranin O staining, were correlated with low levels of CITED2 expression, and strong 
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staining for cleaved aggrecan and type II collagen denaturation (Fig 5.2A). Similarly, CITED2 
was detected in healthy mouse cartilage, but was expressed at low levels in degenerated cartilage 
4 weeks after OA induction by DMM (Fig 5.2B).  
CITED2 suppression produces OA-like changes in normal mouse cartilage.   
We next determined the direct effect of CITED2 suppression on cartilage homeostasis 
after intra-articular injection of CITED2 shRNA in normal mouse knees followed by 
electroporation. Two weeks following CITED2 knockdown, a loss of Safranin O staining was 
detected in the articular cartilage along with a loss of CITED2 expression, an increase in the 
amounts of cleaved aggrecan and denatured type II collagen, compared to the PBS-injected 
contralateral controls (Fig 5.3A).   
Deletion of CITED2 in adult mice results in early OA   
Deletion of Cited2 in the mouse articular cartilage of Cited2 conditional KO (cKO) mice 
was validated at the DNA, mRNA and protein levels 8 weeks after tamoxifen administration 
(data not shown).  Cited2 cKO mice developed early OA as evidenced by histologic analysis 
(OARSI score 1 in cKO vs 0 in wild-type) and Safranin O staining (Fig 5.3B) while the cartilage 
in wild-type controls were healthy.  Cited2 cKO exhibited higher levels of denatured type II 
collagen, aggrecan cleavage as revealed by Col2 ¾M and NITEGE, respectively (Fig 5.3B).   
CITED2 deletion accelerates post-traumatic OA disease progression   
As reduced levels of CITED2 may be associated with the pathogenesis of OA, we 
compared OA disease progression in wild-type and Cited2 KO mice subject to DMM.  Cited2 
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cKO exhibited more severe cartilage degradation and further elevated levels of type II collagen 
denaturation (Col2 3/4M) and aggrecan cleavage (NITEGE) (Fig 5.3C).   
CITED2 suppression upregulates MMP-13 and ADAMTS-5 expression.   
Since CITED2 suppression led to increased damage to both type II collagen and aggrecan 
in the cartilage extracellular matrix, we examined the role of CITED2 in regulating the 
expression of both MMP-13 and ADAMTS-5, which respectively are the most efficient 
proteolytic enzymes which cleave the above mentioned matrix components.  In human and 
mouse OA, reduced levels of CITED2 were associated with increased levels of both MMP-13 
and ADAMTS-5 (Fig 5.4A).  Knockdown of CITED2, by intra-articular gene transfer of 
CITED2 shRNA (Fig 5.4B) or conditional deletion of CITED2 (Fig 5.4C), led to an increase in 
the number of chondrocytes expressing MMP-13 and ADAMTS-5. 
CITED2 represses ADAMTS-5 expression by negatively regulating syndecan-4.   
As CITED2 deletion significantly elevated ADAMTS-5 expression, we explored the 
potential mechanism that CITED2 represses ADAMTS-5 expression, focusing on syndecan-4, 
which is critical for the regulation of ADAMTS-5.187  Immunohistochemical analysis showed 
syndecan-4 is elevated in the cartilage of Cited2 cKO mice and was associated with the increase 
of ADAMTS-5 (Fig 5.5A).  Importantly, gene transfer of Cited2 reduced both syndecan-4 and 
ADAMTS-5 in the articular cartilage, suggesting Cited2 represses ADAMTS-5 by, at least in 
part, negatively regulating syndecan-4 (Fig 5.5B). 
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Discussion 
In this chapter, we showed that levels of CITED2 expression is lower in the cartilage of 
OA patients compared to age- and gender-matched controls. We provide the first evidence that 
reduced CITED2 is associated with cartilage degradation in human OA.  By examining the level 
of CITED2 expression in post-traumatic OA, we found that reduction of CITED2 expression is 
associated with the progression of cartilage degradation.  The consistent results of reduced 
CITED2 expression associated with cartilage degradation in both human and mouse OA suggests 
deficiency of CITED2 may be an important common factor in OA initiation and disease 
progression.  The loss-of-function studies by knocking down CITED2 by intra-articular gene 
transfer in mice provide preliminary, experimental, and direct evidence that deficiency of 
CITED2 is a casual factor of OA.  Furthermore, using genetic deletion of CITED2 in tamoxifen 
inducible, cartilage-specific CITED2 adult knockout mice, we found that deletion of CITED2 
resulted in early OA development after 8 weeks.  Of notice, deletion of a gene specifically from 
the adult cartilage alone seldom generates phenotypic changes.216  This study provides clear and 
strong evidence which indicates that CITED2 is required for cartilage integrity maintenance. 
Cartilage degradation such as in OA is a complex pathologic process.  The initiation and 
progression of which can be, and usually results from more than “one hit” from disease risk 
factors such as aging, overuse, genetics and joint injuries.  Studies have shown that reduced 
CITED2 expression is a function of aging in tendon stem cells, and preliminary studies also 
indicate that levels of CITED2 expression decline with aging in chondrocytes, both in human 
and in mice, suggesting that CITED2 may be an underlying mechanism of aging as a risk factor 
for cartilage degradation in OA. 
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Post-traumatic injuries are a critical risk factor for OA.  Studies show that up to 50% of 
individuals develop OA 10-12 years after injuries to the meniscus or ACL.  In a well established 
post-traumatic OA model based on a meniscus injury, we found that disease progression is 
associated with reduced levels of CITED2 expression, suggesting that deficiency of CITED2 
plays a role in post-traumatic injury-induced OA.  Our data show that deletion of CITED2 in 
adult cartilage combined with a meniscus injury accelerates OA initiation and progression and 
results in a more severe cartilage degradation and OA pathology than CITED2 deletion or DMM 
injury alone.  Taken together, these data suggest that deficiency of CITED2, which may be a 
factor underlying aging and injuries for its role as a cartilage degradation susceptibility factor, or 
may be also a genetic factor which accelerates cartilage degradation when combined with other 
environmental, intrinsic, or extrinsic factors.  
Cartilage degradation in joint diseases such as OA is characterized by an imbalance 
between the anabolic and catabolic activities of chondrocytes, yet the set of regulatory 
mechanisms governing that balance remain incompletely understood.  The finding that 
deficiency of CITED2 is associated with or casually related to upregulation of MMPs, such as 
MMP-13 and ADAMTS such as ADAMTS5 in human and mouse OA suggest CITED2 plays an 
anti-catabolic role via, at least in part, downregulation of these proteolytic enzymes. 
In previous studies, we have identified CITED2 as a transcriptional repressor of MMPs.  
The finding that the upregulation of ADAMTS5 in the CITED2 knockout mice suggest 
aggrecanases such as ADAMTS5 may be another target of CITED2 in its chondroprotective 
pathway.  To this end, our preliminary data indicate CITED2 may downregulate ADAMTS5 in 
chondrocytes by repressing ADAMTS5 activation via syndecan-4.  In addition to its role in 
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suppressing expression of MMPs/ADAMTS reported in this study, CITED2 plays a critical role 
in cell fate determination.  As age is a major risk factor for developing OA, and chondrocyte 
senescence has been suggested to lead to cartilage degradation, further elucidating the role of 
CITED2 in this chondroprotective pathway may not only provide a new avenue for the insight of 
cartilage degradation in arthritic disease, but potential targets for disease prevention and 
treatment. 
Figures 
 
Figure 5.1.  Conditional knockout of Cited2 gene in the cartilage of adult mice. 
Intraperitoneal injections of Tamoxifen (1mg/10g/mouse/day for 5 days) into 6-months-old 
male and female inducible Cited2 conditional KO mice (Col2a1CreERTxCited2fl/fl)64,65 
completely and specifically knocked out the Cited2 gene in mouse articular cartilage. A. 
Mouse crossbreeding strategy. B. Validation of exclusive Cited2 knockout at the DNA, 
mRNA and protein levels 12 weeks after Tamoxifen administration. WT: age and gender 
matched wild type control mice. KO: Col2a1CreERTxCited2fl/fl mice receiving Tamoxifen 
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dissolved in corn oil; Sham: Col2a1CreERTxCited2fl/fl    that received corn oil without 
Tamoxifen.  NC: negative control without sample. 
 
 
 
Figure 5.2.  Reduced levels of CITED2, detected by immunohistochemistry and real-time qPCR 
are associated with increased OA severity, and increased degradation of cartilage matrix 
components aggrecan (NITEGE) and type II collagen (Col2 3/4M) in human OA (A) and mouse 
OA (destabilization of the medial meniscus, DMM) cartilage (B), compared to age and gender-
matched non-OA controls. 
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Figure 5.3.  CITED2 knockdown by intra-articular gene transfer of CITED2 shRNA for 2 weeks 
in wild-type mice (male, C57Bl/6, 10-12 weeks) (A) or conditional knockout of Cited2 (Cited2 
cKO) in the articular cartilage for 8 weeks (male, Cited2flf x Col2al-CreERT, 10-12 weeks) (B) 
led to early OA, and increased the amount of cleaved aggreacan and denatured type II collagen 
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in the articular cartilage compared to sham (A) or wild-type littermates (B).  DMM in Cited2 
cKO mice increased severity of OA and increased cleaved aggrecan and denatured type II 
collagen compared to wild-type littermates (C).   
 
Figure 5.4.  (A) Reductions in CITED2 expression were associated with decreases in 
chondrocytes expressing MMP-13 and ADAMTS5 in human and mouse OA cartilage, compared 
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to non-OA controls.  (B)  Experimental knockdown of Cited2 in mouse articular cartilage by 
intra-articular gene transfer of CITED2 shRNA or (C) conditional knockout led to increases in 
MMP-13 and ADAMTS5 compared to non-knockdown controls. 
 
 
Figure 5.5.  CITED2 represses ADAMTS-5 expression by negatively regulating syndecan-4.  
(A) Level of syndecan-4 was elevated in CITED2 conditional knockout mice (cKO) which was 
associated with elevated levels of ADAMTS5.  (B) CITED2 gene transfer reduced the levels of 
both syndecan-4 and ADAMTS-5 in DMM cartilage.  Cell counts of syndecan-4, ADAMTS-5, 
and CITED2 in conditional knockout mice vs wild-type, and in DMM+vehicle vs. 
DMM+CITED2.  *=p<0.05. 
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Chapter 6 – The Use of CITED2 for Chondroprotection 
Abstract 
 There is currently no cure for degenerative joint diseases which feature the progressive 
degradation of articular cartilage.  So far, most pharmacologic treatments mainly concentrate on 
secondary effects of such diseases, such as relieving pain and improving joint function, but fail 
to address the underlying disease progress.   CITED2, induced by moderate mechanical loading, 
is a transcriptional regulator which suppresses the expression of multiple MMPs and ADAMTS, 
enzymes which directly cleave the cartilage extracellular matrix.  Cartilage degradation, as seen 
in OA, is associated with elevated levels of MMPs and ADAMTS, and reductions in CITED2 
expression.  Experimental knockdown of CITED2 by intra-articular gene transfer of CITED2 
shRNA or genetic deletion of CITED2 in the articular cartilage, led to early cartilage degradation 
and damage to the cartilage extracellular matrix components aggrecan and type II collagen.  In 
this study we tested the hypothesis that restoration of CITED2 would slow progression of 
cartilage degradation.  Gene transfer of CITED2 in two models of cartilage degradation, 
collagen-induced arthritis, and destabilization of the medial meniscus, slowed progression of 
cartilage breakdown.  Immunohistochemistry revealed CITED2 gene transfer also prevented 
degradation to the type II collagen and aggrecan components of the cartilage matrix.  
Furthermore, EGCG, a green tea extract, was a small molecule inducer of CITED2, and daily 
administration of EGCG slowed progression of post-traumatic OA.  Taken together, our studies 
suggest CITED2-based therapies have the potential to arrest or slow cartilage degradation in 
diseases such as osteoarthritis and rheumatoid arthritis. 
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Introduction 
 There is currently no cure for degenerative joint diseases which feature the progressive 
degradation of articular cartilage.77  So far, most pharmacologic treatments mainly concentrate 
on secondary effects of such diseases, such as relieving pain and improving joint function, but 
fail to address the underlying disease progress.217   
Based on the studies in the previous chapters, we have established that: 1) with a unique 
mechanical loading response characteristic and via a newly identified pathway, CITED2 plays a 
novel role in mediating loading-induced MMP downregulation (Chapters 3&4), 2) CITED2 is 
required for cartilage integrity maintenance and CITED2 deficiency was associated with 
cartilage degradation in human OA and post-traumatic OA in mice, knockdown of CITED2 
through intra-articular gene transfer of shCITED2 RNA caused OA like pathologic changes, and 
most importantly, deletion  of CITED2 specifically from adult mouse cartilage resulted in not 
only in OA-like  phenotypic changes, but also accelerated the progression of post-traumatic OA 
(Chapter 5).  3) Furthermore, over-expression of CITED2 represses MMP expression in cultured 
chondrocytes in vitro, suggesting CITED2 is a transcriptional repressor of MMP expression and 
its anti-catabolic action can be triggered by not only mechanical loading, but also by other 
physical or chemical means to protect cartilage.  Together, this suggests that CITED2-based 
therapies may have efficacy in preventing and/or treating cartilage degradation in arthritic 
diseases.   
In this study, we tested the hypothesis that restoration of CITED2 would slow progression of 
cartilage degradation.  To test this, we used intra-articular CITED2 gene transfer in two cartilage 
degradation models:  destabilization of the medial meniscus (DMM), a model of post-traumatic 
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OA, and collagen-induced arthritis (CIA), a model of rheumatoid arthritis.  Furthermore, we 
examined the efficacy of CITED2 in chondroprotection, by administrating epigallocatechin 3-
gallate (EGCG),,218 a hypothesized small molecule activator of CITED2, to mice in the post-
traumatic OA model.  EGCG increases phosphorylation of p38δ,219 a transactivator of CITED2.  
EGCG has also been reported to reduce levels of pro-inflammatory cytokines,220 inhibit 
production of inflammatory mediators,221,222 and suppress expression of several MMPs223 and 
ADAMTS. 224  However, whether EGCG has the capacity to alter OA progression is unknown.   
 
Methods and Materials 
CITED2 gene transfer in mice - CITED2 gene transfer was carried out by weekly intra-articular 
injections of a plasmid encoding CITED2 cDNA (25µg) followed by electroporation (200V, 0.10 
ms pulse length, 4 pulses each polarity) into the DMM knee while the vehicle controls received 
injections of an empty vector followed by electroporation.   
Destabilization of the medial meniscus - One day after the first gene transfer, surgical induction 
of OA (destabilization of the medial meniscus) was performed in the right hind limbs of wild-
type mice (male, 20-24 weeks) as described in Chapter 5.  Immediately after surgery, mice were 
allowed normal cage activity.   
Collagen-induced arthritis (CIA) - Bovine type II collagen solution (Chondrex) was emulsified 
in Freud’s complete adjuvant at 4°C.  Under an IACUC-approved protocol, male Sprague-
Dawley rats (6-8 wk) were immunized by two intradermal injections of 100µl emulsion (1µg 
collagen/µl) at the base of the tail given one week apart. 
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In vivo gene transfer efficiency - In order to determine transfection effiency of in vivo gene 
transfer, 25µg of pcDNA3.1-GFP was injected into the intra-articular cavity of the right knees of 
rats (n=2), followed by electroporation (250V, 0.10 ms pulse length, 4 pulses each polarity).  
Contralateral limbs were injected with an empty vector followed by electroporation.  Forty-eight 
hours after transfection, rats were sacrificed and their hind limbs were fixed in 10% formalin, 
decalcified, and embedded in paraffin.  Sections were cut (5-7μM), mounted on glass slides, 
coverslipped, and visualized under a microscope with a GFP filter. 
CITED2 gene transfer in CIA rats - After the collagen booster injection, and at weekly intervals 
thereafter, rats received 25µg of pcDNA3.1 encoding human wild-type CITED2 cDNA by intra-
articular injection followed by electroporation. Intra-articular injections of an empty vector were 
administered to the contralateral limbs followed by electroporation.  Animals were sacrificed 0, 
8, 11, 14, 17, 21, and 28 days after the first injection (n=2/timepoint). Articular cartilage from 
distal femur and tibial plateau were harvested, flash frozen, and lysed for Western blots.  At Day 
28, parallel articular cartilage samples were fixed in formalin, decalcified and processed for 
histology (n=3/group). 
Induction of osteoarthritis in mice and EGCG treatment - Immediately after the DMM surgery in 
male, 5-6 months mice, 100 μl of EGCG (25mg/kg, Sigma, dissolved in PBS) or vehicle was 
administered via intraperitoneal injection 5 days/week for 4 weeks.  At the end of the 
experiment, hind limbs were fixed in formalin, decalcified and embedded in paraffin 
(n=6/group).  
Immunohistochemistry, Safranin O staining, and OARSI score evaluation - Paraffin sections (5-
7μM) were incubated overnight at 4°C with antibodies against cleaved aggrecan (NITEGE, 
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Ibex), denatured type II collagen (Col2-3/4M, Ibex), MMP-13 (Abcam), and ADAMTS-5 
(Abcam) followed by incubation with anti-mouse or anti-rabbit secondary antibody and 
visualization with DAB chromagen (Vector Laboraties).  Negative controls were stained with 
irrelevant isotype-matched antibodies.  Safranin O-fast green staining was used to visualize 
proteoglycans in the articular cartilage.  OA was severity evaluated by OARSI scoring system225. 
 
Results 
CITED2 gene transfer prevents cartilage degradation in CIA model 
 To determine whether electroporation of CITED2 would prevent cartilage degradation, 
we first established the effectiveness of gene transfer into rat articular cartilage. Forty-eight 
hours after intra-articular gene transfer of a GFP plasmid, we found GFP-producing 
chondrocytes in all three zones of the articular cartilage (Fig 6.1).  Following electroporation, 
CITED2 levels assessed by Western blot increased until Day 14, then remained high throughout 
the experimental period (Fig 6.1).  Collagen-induced arthritis rats treated with CITED2 gene 
transfer, compared to vehicle control, exhibited increased expression of CITED2 in articular 
chondrocytes (81±6% vs. 22±3%, p<0.05), diminished loss of Safranin O staining (OARSI score 
0.18±0.20 vs. 1.12±0.33, p<0.05), lower levels of denatured type II collagen and a reduced 
number of chondrocytes positive for MMP-13 (79±5% vs 40±3%) and ADAMTS5 (89±6% vs. 
51±4%, p<0.05) (Fig 6.1).   
CITED2 gene transfer slows cartilage degradation in DMM model 
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Four weeks after DMM, the articular cartilage in the DMM limb in the vehicle-treated mice 
exhibited Safranin O loss, cartilage fibrillation, and an average OARSI score of 2.5±0.5 (Fig 
6.2).  In contrast, the cartilage in the DMM limb in the CITED2 gene transfer mice exhibited less 
Safranin O loss and cartilage fibrillation, and a lower OARSI score (1.1±0.4, p<0.05) compared 
to vehicle-treated controls (Fig 6.2).   
Immunohistochemical staining showed that CITED2 gene transfer strongly reduced levels of 
cleaved aggrecan (NITEGE) and fragmented/denatured type II collagen (Col2 3/4M), in 
comparison to vehicle-treated controls (Fig 6.2).  These data further confirms that CITED2 gene 
transfer improves the integrity of the articular cartilage by preserving both collagen and aggrecan 
components in post-traumatic OA mice.   
In vivo administration of EGCG slows progression in DMM OA mice 
To confirm EGCG induces expression of CITED2, we treated human C28/I2 chondrocytes 
with 100µM EGCG.  Three hours after treatment, we found expression of CITED2 at the mRNA 
and protein levels was increased (Fig 6.3).   
Four weeks after DMM, the articular cartilage in the DMM limb in the vehicle-treated mice 
exhibited a mild-OA pathological change characterized by Safranin O loss, cartilage fibrillation, 
and an average OARSI score of 2.0±0.5 (Fig 6.4A, B).  In contrast, the cartilage in the DMM 
limb of EGCG-treated mice exhibited less Safranin O loss and cartilage fibrillation, and the 
mean OARSI score (1.2±0.4) was significantly lower compared to vehicle-treated controls 
(p<0.05, Fig 6.4A, B).  Sham-operated mice receiving either vehicle or EGCG treatment did not 
exhibit pathologic changes in the articular cartilage and had OARSI scores of 0.15±0.25 and 
0.12±0.31, respectively (Fig 6.4A, B). 
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Immunohistochemical staining showed that EGCG treatment strongly reduced the levels of 
the type II collagen cleavage epitope (Col2 3/4M) in DMM mice compared to vehicle-treated 
DMM mice (Fig 6.5).  Based on the immunostaining intensities of 6 randomly selected areas of 
the articular cartilage at 4 weeks following DMM, type II collagen cleavage in vehicle-treated 
controls increased to 1.18-fold above sham-treated vehicle mice, and was reduced to 0.97-fold in 
EGCG-treated animals (p<0.05, Fig 6.5A, B).  Sham animals treated with vehicle or EGCG had 
no significant immunostaining for type II collagen degradation at 4 or 8 weeks (Fig 6.5A,B). 
Immunohistochemical staining similarly showed that EGCG treatment reduced the levels of 
cleaved aggrecan (NITEGE) in DMM mice compared to vehicle-treated DMM mice (Fig. 6.6).  
At 4 weeks after DMM, the intensity of aggrecan cleavage was reduced to 1.07-fold in the 
EGCG-treated compared to 1.29-fold in the vehicle control (p=0.08, Fig 6.6A, B).  Sham animals 
treated with vehicle or EGCG did not exhibit significant immunostaining for cleaved aggrecan at 
4 weeks (Fig 6.6A,B). 
 Cartilage matrix degradation is mainly mediated by two major families of proteolytic 
enzymes, namely MMPs and ADAMTS 21.  In particular, MMP-13 is the most potent enzyme in 
cleaving type II collagen, the major form in articular cartilage, while ADAMTS-5 is the 
primarily proteolytic enzyme that cleaves aggrecan, the major proteoglycan in cartilage 77.  We 
therefore examined whether reduction of MMP-13 and ADAMTS5 could underlie the 
chondroprotective effect of EGCG using immunohistochemistry.    
At 4 weeks following DMM, the percentage of MMP-13 positive cells was reduced from 
60% in vehicle-treated mice to 22% in EGCG-treated mice (p<0.05).  MMP-13 positive 
chondrocytes in the vehicle-treated DMM mice were distributed in all three zones of the articular 
cartilage of the femoral and tibial condyles.  In contrast, the MMP-13 positive chondrocytes in 
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EGCG-treated mice were localized mainly in the middle and deep zones (Fig 6.7A, B).  Levels 
of MMP-13 positive cells in the articular cartilage of EGCG-treated sham mice were at a level 
(4%) similar to those in sham vehicle mice (5%) (Fig 6.7A, B).   
 Similarly, at 4 weeks following DMM surgery, EGCG reduced the percentage of 
ADAMTS5 positive cells from 61% in vehicle-treated mice to 22% in the articular cartilage 
(p<0.05, Fig 6.8A, B).  EGCG treatment appeared to exert no measurable effect on the levels of 
ADAMTS5 in chondrocytes in the articular cartilage in the sham animals treated either with 
vehicle (5%) or EGCG (4%) (Fig 6.9A, B).  EGCG did not significantly alter the percentage of 
ADAMTS5 positive cells in sham-operated mice (Fig. 6.8A,B). 
These data further suggest that EGCG treatment improves the integrity of the articular 
cartilage by preserving both collagen and aggrecan components in post-traumatic OA mice, and 
that EGCG exerts chondroprotection, at least in part, by suppressing MMP-13 and ADAMTS5 
expression. 
 
Discussion  
Cartilage degradation is mediated directly by enzymes which cleave the cartilage 
extracellular matrix, such as matrix metalloproteinases (MMPs) and a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS).  Inhibitors for these proteolytic 
enzymes have been explored as therapeutic strategies to treat OA.  However, clinical trials with 
MMP inhibitors so far have been met with limited success and resulted in side effects including 
musculoskeletal pain and inflammation.104-106  These adverse effects have been mainly attributed 
to the lack of selectivity of these inhibitors, and over suppression of their targets.  Matrix 
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metalloproteinases share structural similarities and are susceptible to regulation by broad-
spectrum inhibitors.87  Poor selectivity is problematic because in addition to matrix remodeling, 
MMPs/ADAMTS play important roles in wound healing, angiogenesis, development, 
morphogenesis, and bone remodeling.88,89  Clearly, pharmacologic solutions for treating OA 
need to define the correct molecular targets and ensure proper modulation of these targets.   
The first aims of the studies in this chapter were to test the concept that gain-of-function of 
CITED2 is able to prevent or slow the progression of RA and OA.  It has been established that 
the etiology of OA and RA are different.21  Cartilage degradation in RA is due to high levels of 
inflammatory cytokines.  Different from RA, cartilage degradation in OA can be caused by 
complex risk factors, including genetic, aging, and overuse/trauma.77  While the initiating 
mechanisms for cartilage degradation differ in RA and OA, cartilage destruction is the hallmark 
of both diseases.  In both, activation of MMPs and ADAMTS, the predominant enzyme families 
in directly cleaving the cartilage extracellular matrix, is shared in the molecular pathology.2  Our 
previous studies established a CITED2-mediated pathway in downregulating MMP expression.  
In this study, overexpression of CITED2 not only significantly reduced expression of MMP-13, 
but also ADAMTS-5, a proteolytic enzyme that degrades aggrecans.  Together, the findings in 
this study indicate restoring or elevating CITED2 in inflammatory arthritic joints or in post-
traumatic OA joints can significantly slow cartilage degradation in early phases of the disease, 
but the efficacy of CITED2 in treating cartilage degradation after disease onset remains to be 
tested.   
Our findings suggest that CITED2 exerts great potential for chondroprotection in both RA 
and OA cases; 2) CITED2 plays its role, at least by targeting two major proteolytic enzymes 
MMP-13 and ADAMTS-5, and thus preserves cartilage matrix components type II collagen and 
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aggrecans.  The action of targeting multiple catabolic enzymes may be an underlying mechanism 
for CITED2 as an effective treatment in chondroprotection.  Furthermore, CITED2 selectively 
repressed, but did not completely suppress expression of MMP-13 and ADAMTS-5.  Therefore, 
CITED2-based therapeutic strategies may be a promising treatment that can avoid the adverse 
effects of MMP inhibitors while exerting efficacy in preventing or slowing cartilage degradation.   
Overexpression of CITED2 in articular cartilage proved the concept that CITED2 can be 
used as a molecular target to turn on anti-catabolic action by suppressing not only MMPs but 
also ADAMTS.  However, gene transfer-based therapies are neither patient friendly, or risk-free.  
Furthermore, as inhibiting cartilage degradation in OA and RA may require decades-long 
treatment, long-term use, safety, and convenience are critical criteria for any treatment strategy.  
Based on the multiple-stimuli responsive nature of CITED2, we thought to develop a 
nutraceutical treatment based on the activation of CITED2 and examined efficacy of 
nutraceutical activation in a post-traumatic model of OA.  Through a targeted screening 
approach, we found EGCG, a green tea extract, is an activator of CITED2, and slowed 
progression of post-traumatic OA.  It is unclear whether chondrocytes may be densensitized to 
daily stimulation of EGCG, but this possibility can be tested by monitoring CITED2 levels with 
treatment time. 
EGCG has been used as a general nutritional supplement for anti-cancer, and anti-aging, and 
the dosage of EGCG for such purposes has been proven to be safe and non-toxic.218  In human 
subjects, daily doses of 800mg EGCG for 4 weeks have been reported to be safe and well 
tolerated.226  EGCG is mostly absorbed by the small intestine, and may undergo gastrointestinal 
inactivation.226  Therefore, oral administration of EGCG may reduce its bioavailability.  
Accordingly, in our study, we chose to administer EGCG via intraperitoneal injection, which has 
94 
 
been shown to lead to a higher bioavailability compared to oral consumption.226  Future trials 
should consider optimizing EGCG bioavailability if given orally.  Taking together, this study 
provides direct evidence that CITED2 activation reached by nutraceutical compounds may be a 
valid approach for the prevention and treatment of cartilage degradation. 
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Figures 
 
 
Figure 6.1.  Increased expression of CITED2 by gene transfer exerts chondroprotection in CIA 
rats.  Top:  Experimental protocol, transfection efficiency of CITED2 gene transfer, and 
expression of CITED2 in CIA rats throughout the experiment.  Bottom:  CITED2 gene transfer 
prevented degradative changes within the articular cartilage in the CIA model.  Gene transfer 
prevented loss of Safranin O staining, and decreased expression of MMP-13 and ADAMTS-5. 
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Figure 6.2.  Intra-articular CITED2 gene transfer reduced OA severity, increased CITED2 
expression, and prevented damage to aggrecan and type II collagen in the cartilage of DMM 
mice after 4 weeks, compared to vehicle-treated controls.    
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 Figure 6.3.  Green tea extract, epigallocatechin-3-gallate (EGCG, 100 µM), upregulates 
expression of CITED2 in C28/I2 human chondrocytes.  *p < 0.05 versus control, n=3.    
 
Figure 6.4.  EGCG administration slows progression in early and mid-stage OA in DMM mice.  
Safranin O staining and OARSI score of sham- or DMM-operated mice treated with vehicle or 
EGCG at 4 (A, B) weeks following surgery (*p<0.05, ANOVA, n=6/group).  Arrows heads 
indicate the areas of cartilage fibrillation or erosion, and arrows indicate loss of Safranin O 
staining. 
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 Figure 6.5.  EGCG administration reduced the degradation of type II collagen in the articular 
cartilage matrix.  Immunohistochemical staining of type II collagen cleavage epitope (Col2 
3/4M) and relative staining intensity of the articular cartilage matrix of sham- or DMM-operated 
mice treated with vehicle or EGCG at 4 (A, B) weeks following surgery (*p<0.05, ANOVA, 
n=6/group, Scale bar=100µM). 
 
 
Figure 6.6.  EGCG administration reduced the degradation of aggrecan in the articular cartilage 
matrix.  Immunohistochemical staining of cleaved aggrecan (NITEGE) and relative staining 
intensity in the articular cartilage matrix of sham- or DMM-operated mice treated with vehicle or 
EGCG at 4 (A, B) weeks following surgery (*p<0.05, ANOVA, n=6/group, Scale bar=100µM). 
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 Figure 6.7.  EGCG administration reduced MMP-13 levels in the articular cartilage. 
Immunohistochemical staining of MMP-13 and percentage of MMP-13 positive cells in the 
articular cartilage of sham- or DMM-operated mice treated with vehicle or EGCG at 4 (A, B) 
weeks following surgery (*p<0.05, ANOVA, n=6/group, Scale bar=100µM). 
 
 
Figure 6.8.  EGCG administration reduced ADAMTS5 levels in the articular cartilage. 
Immunohistochemical staining of ADAMTS5 and percentage of ADAMTS5 positive cells in the 
articular cartilage of sham- or DMM-operated mice treated with vehicle or EGCG at 4 (A, B) 
weeks following surgery (*p<0.05, ANOVA, n=6/group, Scale bar=100µM). 
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Chapter 7 – Global Discussion 
Mechanical loading is the most important factor for cartilage homeostasis while 
overloading and underloading are considered to be non-physiologic and lead to cartilage 
degradation.  Moderate loading is required for the maintenance of cartilage integrity, but 
mechanisms mediating these effects are largely unknown. Based on the literature review and our 
previous studies, we hypothesized that CITED2 mediates a mechanical pathway in 
chondroprotection; appropriate levels of CITED2 are critical for cartilage integrity; and 
restoration, or increasing levels of CITED2 exerts efficacy in prevention and treatment for 
cartilage degradation in arthritis.  Accordingly, the gene expression response of CITED2 to 
mechanical loading, the CITED2-mediated mechanically sensitive anti-catabolic pathway, and 
the potential use of CITED2 for chondroprotection were investigated at the molecular, cellular, 
and tissue level in vitro and in vivo in this dissertation. 
 To understand the role of CITED2 in mediating loading-induced MMP downregulation, 
we analyzed CITED2 and MMP expression in immobilized joints with daily, 1hr, remobilization.  
The results that CITED2 downregulation in immobilized limbs was associated with MMP-1 
upregulation and cartilage degradation, and the upregulation of CITED2 associated with the 
downregulation of MMP-1 and chondroprotection was the first hint that CITED2 may play a 
critical role in maintaining cartilage integrity.  We further determined the machinery of this 
mechanical regulation and found that CITED2 regulates MMP expression by competing with 
MMP transactivator Ets-1 for binding to limited amounts of co-activator p300.  The 
mechanotransduction pathway involved the phosphorylation of p38δ, which transactivated 
CITED2 through the HIF-1 and Sp1 binding sites on its promoter region. 
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Upon the establishment and characterization of the biomechanical response of CITED2 
and its critical role in mediating loading-induced downregulation of CITED2 in chondrocytes 
both in vitro and in vivo, we thought that CITED2 deficiency may be a casual factor for cartilage 
degradation, especially considering the case that immobilization caused cartilage degradation 
and was associated with reduced CITED2 expression levels.  This notion was further supported 
by the association of reduced levels of CITED2 and increased levels of MMP-13 and ADAMTS-
5 in human and mouse OA and knockdown of CITED2 via intra-articular injection of CITED2 
shRNA caused OA-like changes in mice (Chapter 5).  We therefore established an inducible and 
cartilage-specific CITED2 knockout mouse model and examined the cartilage to investigate this 
possibility.  The finding that deletion of CITED2 in adult mice results in early OA and further, 
that CITED2 deletion accelerates post-traumatic OA disease progression, provides direct 
evidence that CITED2 is essential for cartilage integrity maintenance and deficiency of CITED2 
is a casual factor of cartilage degradation.  The results also suggest that deficiency of CITED2 
leads to cartilage degradation in OA, at least in part, by reducing the chondrocyte stress-response 
capacity. 
Based on our findings, CITED2 is required for cartilage integrity maintenance, and 
several gain-of-function studies such as overexpressing CITED2 can mimic the effects of 
moderate loading by downregulating expression of MMPs.  We therefore hypothesized that 
CITED2 is a molecular switch / target and activation of CITED2 may prove to be a novel 
strategy for chondroprotection which can be used for preventing and therapeutic treatment of 
cartilage degradation in arthritic disease.  To this end, in Chapter 6, we first conducted 
experiments to prove the concept in inflammatory arthritis by using the collagen-induced arthritis 
model, and we found that weekly intra-articular gene transfer of CITED2 significantly reduced 
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cartilage degradation.  Next, we examined the CITED2 chondroprotection effect in post-
traumatic OA and found a similar efficacy.  Interestingly, gene transfer of CITED2 reduced 
expression of MMP-13 and ADAMTS-5 levels and immunohistochemistry showed such 
treatment reduced aggrecan and type II collagen degradation.  Further, we examined the efficacy 
of a CITED2 activator, EGCG, an extract derived from green tea in OA prevention.  We found 
EGCG treatment slowed progression of OA, and prevented degradation to the cartilage matrix 
components aggrecan and type II collagen, at least in part, by suppressing expression of MMP-
13 and ADAMTS.  This suggests CITED2 can be used as a molecular target via mechanical or 
other means of activation for chondroprotection. 
The unique biomechanical response of CITED2 and the novel pathway that CITED2 
mediates provides novel insight in understanding the underlying mechanisms of cartilage 
homeostasis maintenance, pathogenesis of cartilage degradation, and may be more importantly, a 
potential strategy and molecular target for prevention and treatment of cartilage degradation in 
OA, RA, and other arthritic diseases.   
Based on the studies in this thesis, four major conclusions can be drawn. 
1.  CITED2 was induced in an intensity-dependent manner in response to hydrostatic pressure 
loading, and was required to mediate the loading-induced down-regulation of MMP-1, -2, -3, and 
13.  The overexpression of CITED2 mimicked these anti-catabolic actions of moderate 
mechanical loading. 
2.  Physiological joint loading prevented disuse-caused cartilage degradation associated with 
induced expression of CITED2.  CITED2 exerted its chondroprotective actions by competing 
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with MMP transactivator Ets-1 for binding to limited amounts of co-activator p300, and is 
transactivated by p38δ, through HIF-1α and Sp1 binding sites on its promoter region. 
3.  Deficiency of CITED2 is associated with loss of cartilage integrity in human and mouse OA, 
and experimental knockout of CITED2 led to up-regulation of not only MMP-13 and but 
ADAMTS-5 and resulted in cartilage degradation and OA. 
4.  Restoration of CITED2 slowed progression of cartilage breakdown in post-traumatic OA 
model in mice, and collagen-induced arthritis model in rats, two models of cartilage degradation. 
Activating CITED2, with small molecule EGCG, exerted significant efficacy in 
chondroprotection in also showed slow down the disase progression in post-traumatic OA mice 
model. 
This thesis study focused on the anti-catabolic role of CITED2.  Of notice, as a co-factor, 
CITED2 may also play a role in cartilage homeostasis by regulating chondrocyte fate such as 
chondrocyte hypertrophy senescence, and apoptosis.  Future studies will focus on elucidating 
these cell fate-related mechanisms and determining their role in chondroprotection, which may 
reveal novel insight for understanding the regulatory mechanisms of cartilage homeostasis and 
strategies / targets for the prevention and treatment of cartilage degradation. 
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